

# Product Performance Report

January 2017



# Product Performance Report

January 2017

---

Cardiac Rhythm Management

Pacemakers

ICDs

Leads

# Contents

---

<b>1</b>	<b>Quality Excellence</b>	<b>4</b>
<b>2</b>	<b>Terms and Definitions</b>	<b>6</b>
<b>3</b>	<b>Methodology for Pacemaker and ICD Survival Estimates</b>	<b>8</b>
3.1	Cumulative Survival Probability	8
3.2	Data Acquisition	9
3.3	Returned Product Analysis	10
3.4	Product Performance Graphs and Data	11
<b>4</b>	<b>Performance of BIOTRONIK Pacemakers</b>	<b>12</b>
4.1	Single-Chamber Pacemakers	14
4.2	Dual-Chamber Pacemakers	24
4.3	CRT Pacemakers	35
<b>5</b>	<b>Performance of BIOTRONIK ICDs</b>	<b>38</b>
5.1	Single-Chamber ICDs	40
5.2	Dual-Chamber ICDs	46
5.3	CRT ICDs	56
<b>6</b>	<b>Methodology for Lead Survival Estimates Based on Returned Products and Complaint Data</b>	<b>60</b>
6.1	Cumulative Lead Survival Probability	60
6.2	Lead Data Acquisition	61
6.3	Returned Product Analysis	62
6.4	Lead Complications	63
6.5	Lead Product Performance Graphs and Data	64
<b>7</b>	<b>Performance of BIOTRONIK Leads Based on Returned Products and Complaint Data</b>	<b>66</b>
7.1	Pacing Leads	68
7.2	ICD Leads	86
7.3	CRT Leads	101
<b>8</b>	<b>Methodology for Lead Survival Estimates Based on Clinical Studies</b>	<b>106</b>
8.1	Introduction	106
8.2	BIOTRONIK's Clinical Studies	107
8.3	Lead Complications	110
8.4	Lead Product Performance Graphs and Data	112
<b>9</b>	<b>Performance of BIOTRONIK Leads Based on Clinical Studies</b>	<b>114</b>
9.1	Performance of Pacing Leads	116
9.2	Performance of Defibrillation Leads	117
9.3	Performance of CRT Leads	121
<b>10</b>	<b>Advisories</b>	<b>124</b>
<b>11</b>	<b>X-Ray Identifiers for Pacemakers and ICDs</b>	<b>125</b>
<b>12</b>	<b>Index</b>	<b>126</b>
<b>13</b>	<b>Contacting BIOTRONIK</b>	<b>127</b>

# 1 Quality Excellence

---

BIOTRONIK has a long history of high quality in product design and performance. For more than 50 years, the name BIOTRONIK has been synonymous with excellent workmanship and reliable patient safety. Our quality concept follows an integrated approach and extends from preventative risk measures during a product's development phase through all the steps of the manufacturing and design process.

BIOTRONIK's quality assurance system guarantees strict adherence to internal quality standards as well as compliance with international standards and guidelines. Regular reviews of our product performance and manufacturing evaluations contribute significantly to the achievement of extraordinary quality. Our customers, patients, and physicians can rely on the highest degree of safety built into our products. We always welcome suggestions from users about how we can improve the quality of our products.

This Product Performance Report is an integral component of BIOTRONIK's commitment to provide detailed, accurate information regarding long term reliability. The Product Performance Report exemplifies BIOTRONIK's policy of transparent and timely communication with our customers. As a means to obtain continuous improvement of the

designs, BIOTRONIK carefully analyzes returned products and incorporates all findings into our quality assurance system. This Product Performance Report was prepared in accordance with International Standard ISO 5841-2: 2014 (E)<sup>1</sup> and is in compliance with the recommendations from the U.S. Heart Rhythm Society Task Force on Device Performance Policies and Guidelines. As an active member of AdvaMed and their Pacemaker/ICD Working Group, BIOTRONIK has worked extensively with the CRM industry to ensure comparable product performance data is reported by all manufacturers. The data provided in BIOTRONIK's Product Performance Report incorporates the requirements and definitions as defined in AdvaMed's Requirements for Uniform Reporting of Clinical Performance of Pulse Generators, except as noted herein.

In BIOTRONIK's continuous efforts to provide accurate and transparent information and to ensure that a conservative estimate for device performance is reported, the Survival Probability calculations presented herein also consider reported pacemaker and ICD battery depletions as well as lead complications without the device having been returned for analysis.

<sup>1</sup> The ISO 5841-2:2014(E) is replacing the previous version ISO 5841-2:2000. As part of the update, AdvaMed's Requirements for Uniform Reporting of Clinical Performance of Pulse Generators were incorporated in the new ISO 5841-2:2014(E).



Because a significant portion of this report is based on analyses of returned products, BIOTRONIK urges all physicians to return explanted devices and to notify us when a product is explanted or no longer in use for any reason.

BIOTRONIK aims to continually improve and enhance the scope of this report while integrating the latest information and data concerning the performance of our products. Please contact our U.S. Compliance Department (888) 345-0374 or Worldwide CRM Technical Service Department at [ppr@biotronik.com](mailto:ppr@biotronik.com) with any comments, suggestions or questions regarding this report. Your feedback is highly appreciated and will be used to further develop this report.

BIOTRONIK, January 2017

Dr. Volker Lang  
Vice President Global Quality Management  
BIOTRONIK SE & Co. KG

## 2 Terms and Definitions

---

The following terms and definitions are used for Pacemakers and Implantable Cardioverter Defibrillators (ICDs) as well as pacing and ICD leads throughout this Product Performance Report. These definitions form the basis for this Product Performance Report by clearly articulating the status of each device return and product analysis classification.

### **Elective Replacement Indicator**

All active implantable devices that are powered by an internal battery need to be replaced when their battery is depleted. BIOTRONIK pacemakers and ICDs have an Elective Replacement Indicator (ERI) feature aka Recommended Replacement Time (RRT) that notifies the health care provider when the device's battery is nearing the end of its useful life. Display of ERI is BIOTRONIK's recommendation to the user that the battery's present state will require device replacement in the near future. For further details please refer to the corresponding manual.

### **Battery Depletion**

Battery depletions are classified as either normal (expected) or premature. Premature battery depletions are defined as device malfunctions, while normal battery depletions are not device malfunctions. Batteries of returned devices are considered to have depleted normally when (a) a device is returned with no associated complaint and the device has reached its elective replacement indicator(s) with implant time that meets or exceeds the nominal (50 percentile) predicted longevity at default (labeled) settings, or (b) a device is returned and the device has reached its elective replacement indicator(s) with implant time exceeding 75% of the expected longevity using the longevity calculation tool available at time of product introduction, calculated using the device's actual use conditions and settings. For consistency with previous product performance reports, for ICDs released prior to Lumax and pacemakers released prior to Philos II, batteries of returned devices are considered to have depleted normally if they have reached their elective replacement indicator and testing indicates that the battery and associated circuitry are within specifications.

### **Out of Specification**

Any component or software related event that causes the device's characteristics to not meet pre-defined performance specifications and requirements while implanted and in service. Returned product analysis that determines a device to be out of specification is considered a device malfunction. Normal battery depletions are not considered device malfunctions. BIOTRONIK defines the requirements and performance specifications for each product.

### **Device Malfunctions**

Any component or software related event that causes the device's characteristics to be out of specification while implanted and in service are considered as device malfunctions. Because it is impossible to verify that a device has malfunctioned without analyzing it, only returned devices can be classified as malfunctions for this report. Each returned lead, ICD and pacemaker is analyzed to determine if it has malfunctioned. If the analysis determines that a pacemaker or ICD failed to meet its specifications while implanted and in service, it is further classified as either a malfunction with compromised therapy or as a malfunction without compromised therapy. Devices damaged during implant, revision or after explant, damaged due to external causes (i.e. electrocautery) or due to failure to follow instructions, warnings or contraindications in its associated technical manual are not considered malfunctions. Devices damaged due to interaction with other implanted devices (i.e., leads) are also not considered as malfunctions for the purposes of this Product Performance Report.

### **Malfunctions with Compromised Therapy**

The condition when a pacemaker or ICD is found to have malfunctioned in a manner that compromised pacing or defibrillation therapy (including complete loss or partial degradation) while implanted and in service. Therapy is considered to have been compromised if critical patient-protective pacing or defibrillation therapy is not available. Examples include: sudden loss of battery voltage; accelerated current drain such that a depleted battery was not

---

detected before loss of therapy; sudden malfunction during a tachycardia or fibrillation event resulting in aborted delivery of therapy; intermittent malfunction where therapy is sporadically unavailable.

### **Malfunctions without Compromised Therapy**

The condition when a pacemaker or ICD is found to have malfunctioned in a manner that did not compromise pacing or defibrillation therapy while implanted and in service. Therapy is not compromised as long as critical patient-protective pacing and defibrillation therapies are available as determined through device analysis.

### **Lead Complications**

A lead performance issue where a complaint, associated with at least one of the clinical manifestations listed below, is reported and where the non-returned lead is:

- Verified by medical records to have been implanted and in-service, and
- Reported to have been removed from service,
- Modified to remedy the malfunction, or
- Left in service based on medical judgment.

Complications for leads implanted greater than 30 days are reported as Qualifying lead complications, whereas complications occurring during the first 30 days are reported as Acute lead observations.

In accordance with the latest AdvaMed guidelines and ISO 5841-2:2014(E), the complications are classified in the following categories:

- Failure to Capture
- Failure to Sense
- Oversensing
- Abnormal Pacing Impedance
- Abnormal Defibrillation Impedance
- Insulation Breach
- Conductor Fracture
- Lead Dislodgement
- Extracardiac Stimulation
- Cardiac Perforation
- Other

### **Survival Probability Estimates**

The probability that a device remains operational during a discrete time interval is defined as survival

probability. Survival probability, as presented in this report, is related to device survival only and not survival of the patient. The survival probability estimates in this report are based on BIOTRONIK's analysis of returned products as well as events that are reported to BIOTRONIK (e.g., battery depletions or lead complications).

### **Cumulative Survival Probability Estimates**

The survival probability over a device's service time is the cumulative survival probability. It is calculated from all discrete survival probabilities of previous time intervals. This characteristic is calculated separately for malfunction-free survival and all-cause survival (including normal battery depletions). Specific populations that are subject to a safety advisory notification are excluded and shown separately.

### **Implanted Devices**

Only devices remaining implanted for at least one calendar day after the implantation date are considered as implanted. Devices that are removed from the patient on the same calendar day as the implant procedure do not contribute to the survival statistics.

### **Active Implants**

The number of devices that remain operational within a discrete observation interval are active implants. Units are removed from this cohort due to patient death or explant for any reason.

### **Underreporting**

A device status may change without being accounted for in the Product Performance database due to a lack of information being provided to BIOTRONIK. Underreporting adjustments deemed to be necessary are detailed in this report.

### **Safety Advisory Notifications**

Any action taken by the manufacturer to inform clinicians concerning a device performance issue that may cause the device to not meet its predefined specifications is referred to as a Safety Advisory Notification.

# 3 Methodology for Pacemaker and ICD Survival Estimates

## 3.1 Cumulative Survival Probability

---

This report has been prepared in accordance with ISO 5841-2:2014(E) applying actuarial analysis for the calculation of survival probabilities. Survival estimates given in this report are considered to be generally representative for worldwide performance of BIOTRONIK devices.

The Cumulative Survival Probability is an estimate based on the percentage of pacemakers and ICDs that remain implanted and operational at various points of the product's service time in absence of concurrent events such as morbidity and voluntary explants for various reasons (e.g., device upgrade). The Device Survival Estimate over time is displayed in cumulative curves (Kaplan-Meier). The product's performance is evaluated in discrete one-month intervals. The survival probability for each month is given by the number of devices that remain implanted and operational through this month divided by the number of devices that entered the interval. The cumulative survival probability for any period is given by multiplying all survival probabilities of previous months.

At the time of implantation, the cumulative survival probability is 100 %. Even though they are analyzed as part of our quality system monitoring, devices that are found to be out of specification prior to or during the implantation procedure are removed from the statistics as they do not contribute to a patient's risk of being subject to a device malfunction or replacement during the device's service time. Because this report is provided to describe product performance based on returned product analyses, the pacemaker and ICD data does not include information regarding medical complications such as erosion, infection or diaphragmatic stimulation.

In general, during the initial phase of the service time, devices which are out of specification are the primary contribution to reduction of survival probability. As the product lifecycle lengthens, normal battery depletion assumes a greater impact on the survival curve and becomes the dominating factor.

In order to make these two effects distinguishable, the cumulative survival probability curves are shown separately for devices that are confirmed to have malfunctioned only, and for total (all-cause) cumulative survival. In case of a device being subject to a safety advisory notification that significantly impacts the survival probability, this factor is displayed separately.



## 3.2 Data Acquisition

---

This report is based on the observation of BIOTRONIK's U.S. products through review of our device registration and tracking systems and analyses of returned products from all sources. Because the ability to perform decedent searches of patients with BIOTRONIK devices via the U.S. Social Security Administration, the use of U.S. data more accurately represents the active patient population for reporting purposes. In addition, device tracking regulations and vigilance reporting regulations vary throughout the world; therefore use of the U.S. data is most appropriate for accurate and consistent reporting of product performance.

In order to be included in the population under observation, a device must be registered and implanted for at least one calendar day. The cutoff date for the data included in this report is June 30, 2016. The number of U.S. devices that are implanted and remain active as well as the total number of products distributed worldwide are provided for each product family in this report. Information is provided for separate product families, in that devices with nearly identical hardware and therapy functions are combined. For example, Lexos VR and VR-T (with Home Monitoring) ICDs are combined into a single family, Lexos Single Chamber ICDs.

Survival estimates are calculated for product families having accumulated at least 10,000 cumulative implant months. Because 10,000 implant months may take some time to accumulate, there may be a gap between U.S. market release and the start of graphical representation of survival probability. Products no longer being distributed with less than 500 active implants may be excluded from this report.

ISO 5841-2 describes a method for adjusting the device survival probability to compensate for underreported malfunctions and unrelated patient deaths. The factor for underreporting of malfunctions is unknown as currently no systematic data is available that reveals this factor. Consequently, this factor remains unaccounted for this report. Patient mortality is artificially elevated if the reported rate from our registration and tracking systems is below the annual mortality in clinical studies. Normal battery depletion rate is assumed if the reported rate of depletion decreases over time.

## 3.3 Returned Product Analysis

---

Information on malfunctioning for the pacemaker and ICD portions of this report is taken exclusively from the analysis of returned products. The outcome of this analysis is the basis for the final classification of the device's cause of explantation. Only analyzed products with confirmed device malfunctions are utilized in the calculation of malfunction-free survival probability.

Every pacemaker and ICD returned to BIOTRONIK is analyzed per internal procedures and classified as functioning normally, normal battery depletion, or malfunctioning (including premature battery depletion) while implanted and in service. These device classifications are the basis for BIOTRONIK's cumulative survival estimates on pacemakers and ICDs.

As a significant portion of pacemakers and ICDs with normal battery depletion are not returned for analysis, BIOTRONIK also considers unconfirmed pacemaker and ICD battery depletions (reported, but device not returned) in the total survival estimates to ensure that a conservative estimate for device performance is reported.

## 3.4 Product Performance Graphs and Data

---

The product performance information is shown in each section in alphabetical order and by product type.

For each product, the report provides:

- Product versions that contribute to the evaluation
- U.S. and CE market release dates
- Worldwide quantity of products that have been distributed
- U.S. registered implants (number of products included in this report)
- Estimated active U.S. implants
- Number of U.S. normal battery depletions
- Number of U.S. confirmed malfunctions

The survival plots provide:

### 1. Total Survival

The combined cumulative survival probability for all causes that result in device removal or a system out of operation, excluding removals for clinical reasons unrelated to the device's performance (i.e., infections).

### 2. Malfunction-Free Survival

The cumulative survival probability free of component or software malfunctions excluding normal battery depletions, but including premature battery depletions. Normal battery depletions only have an impact on the total cumulative survival.

Products or subgroups of products may become subject to safety advisory notifications that can significantly impact the overall product performance. However, as these subgroups are clearly defined they are separated from the non-advisory devices. The impact of the advisory notification is then shown in a separate graph for total cumulative survival and for malfunction-free survival of the device population affected by the advisory notification. Current advisories are listed in chapter 11 of this report.

The cumulative survival data and the 95% confidence intervals according to the Greenwood's formula<sup>1</sup> are shown in numerical form for the observed population.

<sup>1</sup> Greenwood, M. The natural duration of cancer. Reports on Public Health and Medical Subjects 33, London: Her Majesty's Stationery Office, 1-26, 1926.

## 4 Performance of BIOTRONIK Pacemakers

---



- 
- 4.1 Single-Chamber Pacemakers
  - 4.2 Dual-Chamber Pacemakers
  - 4.3 CRT Pacemakers


## 4.1 Single-Chamber Pacemakers

### Actros

#### Product Details

Product Versions	S, SR
NBG Code(s)	SSI, SSIR
U.S. Market Release	Mar 1998
CE Market Release	Apr 1997
Worldwide Distributed Devices	125000
Registered U.S. Implants	6750
Estimated Active U.S. Implants	942
U.S. Normal Battery Depletions	402

	Quantity	Rate
U.S. Confirmed Malfunctions	2	0.03%
■ Therapy Compromised	0	0.00%
■ Therapy Available	2	0.03%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.	14 yr.	15 yr.	16 yr.	17 yr.
Total Survival [%]	100.0	100.0	99.9	99.9	99.7	99.2	98.6	97.0	94.2	90.0	84.2	78.3	71.0	62.5	53.1	43.3	33.6	24.6
[95% Confidence Interval]			±0.1	±0.1	±0.2	±0.3	±0.4	±0.7	±1.0	±1.3	±1.6	±1.8	±1.8	±1.6	±1.4	±1.1	±0.9	±0.6
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9
[95% Confidence Interval]								±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1


## 4.1 Single-Chamber Pacemakers

### Axios

#### Product Details

Product Versions	S, SR
NBG Code(s)	SSI, SSIR
U.S. Market Release	Nov 2001
CE Market Release	Oct 2001
Worldwide Distributed Devices	142 000
Registered U.S. Implants	1 370
Estimated Active U.S. Implants	308
U.S. Normal Battery Depletions	70

	Quantity	Rate
U.S. Confirmed Malfunctions	1	0.07%
■ Therapy Compromised	0	0.00%
■ Therapy Available	1	0.07%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.
Total Survival [%]	100.0	100.0	100.0	99.9	99.9	99.3	98.9	98.7	96.8	94.5	89.7	84.1	77.4
[95% Confidence Interval]				±0.2	±0.2	±0.7	±0.8	±0.9	±1.5	±2.0	±2.8	±3.2	±3.3
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.8	99.8	99.8	99.8	99.8
[95% Confidence Interval]									±0.4	±0.4	±0.4	±0.4	±0.4

## 4.1 Single-Chamber Pacemakers


### Cylos and Cylos 990

#### Product Details

Product Versions*	VR, 990 VR
NBG Code(s)	WIR
U.S. Market Release	Jan 2006
CE Market Release	Nov 2005 / Mar 2008
Worldwide Distributed Devices	25 900
Registered U.S. Implants	6 150
Estimated Active U.S. Implants	3 300
U.S. Normal Battery Depletions	368

	Quantity	Rate
U.S. Confirmed Malfunctions	4	0.07%
■ Therapy Compromised	1	0.02%
■ Therapy Available	3	0.05%

\* While Cylos 990 VR is not distributed in the U.S., the performance is expected to be similar to the U.S. distributed products



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.
Total Survival [%]	100.0	100.0	100.0	99.9	99.6	99.5	98.7	94.6	85.6	71.9
[95% Confidence Interval]			±0.1	±0.1	±0.2	±0.2	±0.3	±0.8	±1.5	±1.7
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	99.9	99.9	99.9	99.9	99.9	99.9
[95% Confidence Interval]			±0.0	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1




## 4.1 Single-Chamber Pacemakers

### Eluna 8

#### Product Details

Product Versions	SR, SR-T
NBG Code(s)	AAIR, WIR
U.S. Market Release	Dec 2014
CE Market Release	Aug 2014
Worldwide Distributed Devices	9 800
Registered U.S. Implants	2 190
Estimated Active U.S. Implants	2 110
U.S. Normal Battery Depletions	0

	Quantity	Rate
U.S. Confirmed Malfunctions	0	0.00%
■ Therapy Compromised	0	0.00%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.
Total Survival [%]	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1


## 4.1 Single-Chamber Pacemakers

### Entovis

#### Product Details

Product Versions	SR, SR-T
NBG Code(s)	AAIR, WIR
U.S. Market Release	Jun 2010
CE Market Release	Nov 2009
Worldwide Distributed Devices	27900
Registered U.S. Implants	2340
Estimated Active U.S. Implants	2110
U.S. Normal Battery Depletions	0

	Quantity	Rate
U.S. Confirmed Malfunctions	0	0.00%
■ Therapy Compromised	0	0,00%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.
Total Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1


## 4.1 Single-Chamber Pacemakers

### Estella

#### Product Details

Product Versions	SR, SR-T
NBG Code(s)	AAIR, WIR
U.S. Market Release	Feb 2011
CE Market Release	Feb 2011
Worldwide Distributed Devices	18 800
Registered U.S. Implants	609
Estimated Active U.S. Implants	463
U.S. Normal Battery Depletions	1

	Quantity	Rate
U.S. Confirmed Malfunctions	1	0.16%
■ Therapy Compromised	0	0.00%
■ Therapy Available	1	0.16%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.
Total Survival [%]	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1


## 4.1 Single-Chamber Pacemakers

### Evia

#### Product Details

Product Versions	SR, SR-T
NBG Code(s)	AAIR, WIR
U.S. Market Release	May 2010
CE Market Release	Oct 2009
Worldwide Distributed Devices	55800
Registered U.S. Implants	12000
Estimated Active U.S. Implants	9660
U.S. Normal Battery Depletions	5

	Quantity	Rate
U.S. Confirmed Malfunctions	1	0.01%
■ Therapy Compromised	1	0.01%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1

## 4.1 Single-Chamber Pacemakers


### Philos II and Talos

#### Product Details

Product Versions*	S, SR
NBG Code(s)	SSI, SSIR
U.S. Market Release	Sep 2004
CE Market Release	Feb 2004 / May 2006
Worldwide Distributed Devices	211 000
Registered U.S. Implants	5 240
Estimated Active U.S. Implants	2 950
U.S. Normal Battery Depletions	123

	Quantity	Rate
U.S. Confirmed Malfunctions	1	0.02%
■ Therapy Compromised	1	0.02%
■ Therapy Available	0	0.00%

\* While Talos SR and Talos S are not distributed in the U.S., their performance is expected to be similar to the U.S. distributed products



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	100.0	99.8	99.8	99.4	99.1	98.5	97.7	94.7	90.4
[95% Confidence Interval]				±0.1	±0.1	±0.2	±0.3	±0.4	±0.6	±1.0	±1.7
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
[95% Confidence Interval]											


## 4.1 Single-Chamber Pacemakers

### Philos

#### Product Details

Product Versions	S, SR
NBG Code(s)	SSI, SSIR
U.S. Market Release	Sep 2000
CE Market Release	Aug 2000
Worldwide Distributed Devices	109 000
Registered U.S. Implants	5 770
Estimated Active U.S. Implants	1 640
U.S. Normal Battery Depletions	238

	Quantity	Rate
U.S. Confirmed Malfunctions	7	0.12%
■ Therapy Compromised	0	0.00%
■ Therapy Available	7	0.12%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.	14 yr.
Total Survival [%]	100.0	99.9	99.8	99.7	99.6	99.4	98.9	98.5	97.8	96.3	92.5	87.9	82.7	76.5	69.1
[95% Confidence Interval]		±0.1	±0.1	±0.2	±0.2	±0.3	±0.4	±0.4	±0.6	±0.8	±1.2	±1.5	±1.8	±1.7	±1.6
Malfunction-Free Survival [%]	100.0	99.9	99.9	99.9	99.9	99.9	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1


## 4.1 Single-Chamber Pacemakers

### Protos

#### Product Details

Product Versions	VR/CLS
NBG Code(s)	WIR
U.S. Market Release	Jan 2003
CE Market Release	Jul 2003
Worldwide Distributed Devices	9820
Registered U.S. Implants	3260
Estimated Active U.S. Implants	812
U.S. Normal Battery Depletions	306

	Quantity	Rate
U.S. Confirmed Malfunctions	6	0.18%
■ Therapy Compromised	2	0.06%
■ Therapy Available	4	0.12%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.
Total Survival [%]	100.0	100.0	99.9	99.8	99.3	98.7	97.1	89.2	81.0	71.5	58.9	44.1	29.1
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.2	±0.4	±0.5	±0.8	±1.6	±2.0	±2.0	±1.7	±1.3	±0.9
Malfunction-Free Survival [%]	100.0	100.0	99.9	99.9	99.8	99.8	99.7	99.7	99.7	99.7	99.7	99.7	99.7
[95% Confidence Interval]			±0.1	±0.1	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2


## 4.2 Dual-Chamber Pacemakers

### Actros

#### Product Details

Product Versions	D, DR, SLR
NBG Code(s)	DDD, DDDR, VDDR
U.S. Market Release	Mar 1998
CE Market Release	Apr 1997
Worldwide Distributed Devices	108000
Registered U.S. Implants	13700
Estimated Active U.S. Implants	2000
U.S. Normal Battery Depletions	2575

	Quantity	Rate
U.S. Confirmed Malfunctions	3	0.02%
■ Therapy Compromised	3	0.02%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.	14 yr.	15 yr.	16 yr.
Total Survival [%]	100.0	100.0	99.9	99.8	99.2	97.3	91.7	81.6	70.0	55.9	39.6	23.8	11.5	4.1	1.0	0.2	0.0
[95% Confidence Interval]				±0.1	±0.2	±0.3	±0.6	±0.9	±1.1	±1.1	±0.9	±0.5	±0.3	±0.1			
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
[95% Confidence Interval]																	




## 4.2 Dual-Chamber Pacemakers

### Axios

#### Product Details

Product Versions	D, DR, SLR
NBG Code(s)	DDD, DDDR, VDDR
U.S. Market Release	Nov 2001
CE Market Release	Oct 2001
Worldwide Distributed Devices	110000
Registered U.S. Implants	2750
Estimated Active U.S. Implants	569
U.S. Normal Battery Depletions	324

	Quantity	Rate
U.S. Confirmed Malfunctions	2	0.07%
■ Therapy Compromised	0	0.00%
■ Therapy Available	2	0.07%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.
Total Survival [%]	100.0	100.0	99.9	99.8	99.4	98.7	96.7	93.9	89.1	82.2	73.4	63.6	52.5	40.9
[95% Confidence Interval]		±0.1	±0.1	±0.2	±0.3	±0.5	±0.9	±1.2	±1.7	±2.2	±2.5	±2.4	±2.1	±1.7
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9
[95% Confidence Interval]						±0.1	±0.1	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2

## 4.2 Dual-Chamber Pacemakers


### Cylos and Cylos 990

#### Product Details

Product Versions*	DR, DR-T
NBG Code(s)	DDDR
U.S. Market Release	Jan 2006
CE Market Release	Nov 2005 / Mar 2008
Worldwide Distributed Devices	81 300
Registered U.S. Implants	30 400
Estimated Active U.S. Implants	13 100
U.S. Normal Battery Depletions	4 849

	Quantity	Rate
U.S. Confirmed Malfunctions	27	0.09%
■ Therapy Compromised	7	0.02%
■ Therapy Available	20	0.07%

\* While Cylos 990 DR and Cylos 990 DR-T are not distributed in the U.S., the performance is expected to be similar to the U.S. distributed products



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.
Total Survival [%]	100.0	99.9	99.9	99.8	99.4	98.1	91.7	75.6	53.9
[95% Confidence Interval]				±0.1	±0.1	±0.2	±0.4	±0.7	±0.9
Malfunction-Free Survival [%]	100.0	100.0	100.0	99.9	99.9	99.9	99.9	99.9	99.9
[95% Confidence Interval]									


## 4.2 Dual-Chamber Pacemakers

### Eluna 8

#### Product Details

Product Versions	DR, DR-T
NBG Code(s)	DDDR
U.S. Market Release	Dec 2014
CE Market Release	Aug 2014
Worldwide Distributed Devices	43 300
Registered U.S. Implants	15 000
Estimated Active U.S. Implants	14 500
U.S. Normal Battery Depletions	1

	Quantity	Rate
U.S. Confirmed Malfunctions	0	0.00%
■ Therapy Compromised	0	0.00%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.
Total Survival [%]	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1


## 4.2 Dual-Chamber Pacemakers

### Entovis

#### Product Details

Product Versions	DR, DR-T
NBG Code(s)	DDDR
U.S. Market Release	Feb 2010
CE Market Release	Nov 2009
Worldwide Distributed Devices	105000
Registered U.S. Implants	11900
Estimated Active U.S. Implants	10800
U.S. Normal Battery Depletions	1

	Quantity	Rate
U.S. Confirmed Malfunctions	1	0.01%
■ Therapy Compromised	0	0.00%
■ Therapy Available	1	0.01%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.
Total Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1


## 4.2 Dual-Chamber Pacemakers

### Estella

#### Product Details

Product Versions	DR, DR-T
NBG Code(s)	DDDR
U.S. Market Release	Feb 2011
CE Market Release	Feb 2011
Worldwide Distributed Devices	26 500
Registered U.S. Implants	2 940
Estimated Active U.S. Implants	2 370
U.S. Normal Battery Depletions	5

	Quantity	Rate
U.S. Confirmed Malfunctions	1	0.03%
■ Therapy Compromised	0	0.00%
■ Therapy Available	1	0.03%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.1


## 4.2 Dual-Chamber Pacemakers

### Etrinsa 8

#### Product Details

Product Versions	DR-T
NBG Code(s)	DDDR
U.S. Market Release	Dec 2014
CE Market Release	Aug 2014
Worldwide Distributed Devices	36 300
Registered U.S. Implants	5 170
Estimated Active U.S. Implants	5 060
U.S. Normal Battery Depletions	0

	Quantity	Rate
U.S. Confirmed Malfunctions	0	0.00%
■ Therapy Compromised	0	0.00%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.
Total Survival [%]	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1


## 4.2 Dual-Chamber Pacemakers

### Evia

#### Product Details

Product Versions	DR, DR-T
NBG Code(s)	DDDR
U.S. Market Release	May 2010
CE Market Release	Oct 2009
Worldwide Distributed Devices	193000
Registered U.S. Implants	61900
Estimated Active U.S. Implants	50800
U.S. Normal Battery Depletions	73

	Quantity	Rate
U.S. Confirmed Malfunctions	18	0.03%
■ Therapy Compromised	10	0.02%
■ Therapy Available	8	0.01%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1


## 4.2 Dual-Chamber Pacemakers

### Philos

#### Product Details

Product Versions	D, DR, DR-T, SLR
NBG Code(s)	DDD, DDDR, VDDR
U.S. Market Release	Sep 2000
CE Market Release	Aug 2000
Worldwide Distributed Devices	172000
Registered U.S. Implants	20700
Estimated Active U.S. Implants	5580
U.S. Normal Battery Depletions	2366

	Quantity	Rate
U.S. Confirmed Malfunctions	28	0.14%
■ Therapy Compromised	5	0.02%
■ Therapy Available	23	0.11%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.	14 yr.	15 yr.
Total Survival [%]	100.0	100.0	99.9	99.8	99.3	98.4	96.7	93.5	88.7	81.7	74.1	65.5	55.6	45.1	34.6	24.9
[95% Confidence Interval]				±0.1	±0.1	±0.2	±0.3	±0.4	±0.6	±0.8	±0.9	±0.8	±0.7	±0.6	±0.5	±0.3
Malfunction-Free Survival [%]	100.0	100.0	100.0	99.9	99.9	99.9	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8	99.8
[95% Confidence Interval]						±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1



## 4.2 Dual-Chamber Pacemakers


### Philos II and Talos

#### Product Details

Product Versions*	D, DR, DR-T (Philos II only), SLR
NBG Code(s)	DDD, DDDR, VDDR
U.S. Market Release	Sep 2004
CE Market Release	Feb 2004 / May 2006
Worldwide Distributed Devices	363 000
Registered U.S. Implants	23 200
Estimated Active U.S. Implants	11 100
U.S. Normal Battery Depletions	2 475

	Quantity	Rate
U.S. Confirmed Malfunctions	21	0.09%
■ Therapy Compromised	0	0.00%
■ Therapy Available	21	0.09%

\* While Philos II SLR, Talos D, Talos DR and Talos SLR are not distributed in the U.S., their performance is expected to be similar to the U.S. distributed products



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	100.0	99.9	99.8	99.6	99.1	98.0	94.0	85.8	73.0	55.9
[95% Confidence Interval]				±0.1	±0.1	±0.1	±0.2	±0.4	±0.7	±1.0	±1.1
Malfunction-Free Survival [%]	100.0	100.0	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9
[95% Confidence Interval]										±0.1	±0.1


## 4.2 Dual-Chamber Pacemakers

### Protos

#### Product Details

Product Versions	DR/CLS
NBG Code(s)	DDDR
U.S. Market Release	Jan 2003
CE Market Release	Jul 2003
Worldwide Distributed Devices	27800
Registered U.S. Implants	10800
Estimated Active U.S. Implants	2560
U.S. Normal Battery Depletions	1903

	Quantity	Rate
U.S. Confirmed Malfunctions	10	0.09%
■ Therapy Compromised	2	0.02%
■ Therapy Available	8	0.07%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.
Total Survival [%]	100.0	99.9	99.8	99.5	98.5	95.7	86.4	73.8	58.4	39.8	22.1	9.2	2.6	0.4
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.3	±0.5	±0.8	±1.1	±1.0	±0.7	±0.4	±0.2		
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9
[95% Confidence Interval]					±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1


## 4.3 CRT Pacemakers

### Evia

#### Product Details

Product Versions	HF, HF-T
NBG Code(s)	DDDRV
U.S. Market Release	May 2010
CE Market Release	Oct 2009
Worldwide Distributed Devices	8200
Registered U.S. Implants	2250
Estimated Active U.S. Implants	1740
U.S. Normal Battery Depletions	9

	Quantity	Rate
U.S. Confirmed Malfunctions	0	0.00%
■ Therapy Compromised	0	0.00%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.
Total Survival [%]	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1


## 4.3 CRT Pacemakers

### Stratos

#### Product Details

Product Versions	LV, LV-T
NBG Code(s)	DDDRV
U.S. Market Release	May 2008
CE Market Release	Nov 2002
Worldwide Distributed Devices	21 400
Registered U.S. Implants	1 310
Estimated Active U.S. Implants	561
U.S. Normal Battery Depletions	136

	Quantity	Rate
U.S. Confirmed Malfunctions	1	0.08%
■ Therapy Compromised	0	0.00%
■ Therapy Available	1	0.08%




Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.
Total Survival [%]	100.0	99.9	98.8	96.5	93.4	86.1
[95% Confidence Interval]		±0.2	±0.7	±1.2	±1.6	±2.8
Malfunction-Free Survival [%]	100.0	99.9	99.9	99.9	99.9	99.9
[95% Confidence Interval]		±0.2	±0.2	±0.2	±0.2	±0.2



## 5 Performance of BIOTRONIK ICDs

---



---

5.1 Single-Chamber ICDs

5.2 Dual-Chamber ICDs

5.3 CRT ICDs


## 5.1 Single-Chamber ICDs

### Ilesto 7

#### Product Details

Product Versions	VR-T
NBG Code(s)	WE-VWIR
Maximum Energy [J]	40
U.S. Market Release	Sep 2013
CE Market Release	Jun 2013
Worldwide Distributed Devices	3040
Registered U.S. Implants	1270
Estimated Active U.S. Implants	1150
U.S. Normal Battery Depletions	2

	Quantity	Rate
U.S. Confirmed Malfunctions	0	0.00%
■ Therapy Compromised	0	0.00%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.
Total Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1




## 5.1 Single-Chamber ICDs

### Lexos

#### Product Details

Product Versions	VR, VR-T
NBG Code(s)	WIRD
Maximum Energy [J]	30
U.S. Market Release	Feb 2004
CE Market Release	Oct 2003
Worldwide Distributed Devices	16 800
Registered U.S. Implants	1 250
Estimated Active U.S. Implants	344
U.S. Normal Battery Depletions	150

	Quantity	Rate
U.S. Confirmed Malfunctions	0	0.00%
■ Therapy Compromised	0	0.00%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.7	99.4	98.7	94.9	82.0	61.7	33.7	10.3	1.2
[95% Confidence Interval]		±0.2	±0.3	±0.5	±0.7	±1.5	±2.7	±2.5	±1.4	±0.4	
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
[95% Confidence Interval]											


## 5.1 Single-Chamber ICDs

### Lumax 340

#### Product Details

Product Versions	VR, VR-T
NBG Code(s)	WE-VVIR
Maximum Energy [J]	40
U.S. Market Release	Feb 2007
CE Market Release	Feb 2007
Worldwide Distributed Devices	27 100
Registered U.S. Implants	3 990
Estimated Active U.S. Implants	1 340
U.S. Normal Battery Depletions	656

	Quantity	Rate
U.S. Confirmed Malfunctions	6	0.15%
■ Therapy Compromised	4	0.10%
■ Therapy Available	2	0.05%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.
Total Survival [%]	100.0	99.8	99.6	99.3	98.5	95.2	74.3	40.7
[95% Confidence Interval]		±0.2	±0.2	±0.3	±0.4	±0.8	±1.9	±1.3
Malfunction-Free Survival [%]	100.0	99.9	99.9	99.9	99.8	99.8	99.8	99.8
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1


## 5.1 Single-Chamber ICDs

### Lumax 540

#### Product Details

Product Versions	VR-T
NBG Code(s)	WE-WVIR
Maximum Energy [J]	40
U.S. Market Release	May 2009
CE Market Release	Jun 2008
Worldwide Distributed Devices	19 400
Registered U.S. Implants	4 550
Estimated Active U.S. Implants	3 190
U.S. Normal Battery Depletions	25

	Quantity	Rate
U.S. Confirmed Malfunctions	5	0.11%
■ Therapy Compromised	4	0.09%
■ Therapy Available	1	0.02%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.
Total Survival [%]	100.0	100.0	100.0	99.9	99.9	99.8	99.8
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0	99.9	99.9	99.8	99.8
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1


## 5.1 Single-Chamber ICDs

### Lumax 740

#### Product Details

Product Versions	VR-T
NBG Code(s)	WE-VWIR
Maximum Energy [J]	40
U.S. Market Release	Sep 2012
CE Market Release	Apr 2012
Worldwide Distributed Devices	4 740
Registered U.S. Implants	1 580
Estimated Active U.S. Implants	1 280
U.S. Normal Battery Depletions	1

	Quantity	Rate
U.S. Confirmed Malfunctions	0	0.00%
■ Therapy Compromised	0	0.00%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.
Total Survival [%]	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1


## 5.1 Single-Chamber ICDs

### Lumos

#### Product Details

Product Versions	VR-T
NBG Code(s)	VE-WVIR
Maximum Energy [J]	30
U.S. Market Release	Sep 2005
CE Market Release	May 2005
Worldwide Distributed Devices	8 600
Registered U.S. Implants	1 780
Estimated Active U.S. Implants	473
U.S. Normal Battery Depletions	282

	Quantity	Rate
U.S. Confirmed Malfunctions	1	0.06%
■ Therapy Compromised	0	0.00%
■ Therapy Available	1	0.06%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.
Total Survival [%]	100.0	99.9	99.8	99.4	98.3	92.6	76.5	55.0	28.1	7.9
[95% Confidence Interval]		±0.2	±0.2	±0.4	±0.7	±1.5	±2.5	±2.0	±1.1	±0.3
Malfunction-Free Survival [%]	100.0	100.0	100.0	99.9	99.9	99.9	99.9	99.9	99.9	99.9
[95% Confidence Interval]				±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1


## 5.2 Dual-Chamber ICDs

### Iforia 7 DX

#### Product Details

Product Versions	VR-T
NBG Code(s)	WE-VDDR
Maximum Energy [J]	40
U.S. Market Release	Sep 2013
CE Market Release	Jun 2013
Worldwide Distributed Devices	2270
Registered U.S. Implants	1450
Estimated Active U.S. Implants	1360
U.S. Normal Battery Depletions	0

	Quantity	Rate
U.S. Confirmed Malfunctions	2	0.14%
■ Therapy Compromised	2	0.14%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.
Total Survival [%]	99.9	99.9
[95% Confidence Interval]	±0.1	±0.1
Malfunction-Free Survival [%]	99.9	99.9
[95% Confidence Interval]	±0.1	±0.1


## 5.2 Dual-Chamber ICDs

### Ilesto 7

#### Product Details

Product Versions	DR-T
NBG Code(s)	WE-VDDR
Maximum Energy [J]	40
U.S. Market Release	Sep 2013
CE Market Release	Jun 2013
Worldwide Distributed Devices	5090
Registered U.S. Implants	3470
Estimated Active U.S. Implants	3060
U.S. Normal Battery Depletions	1

	Quantity	Rate
U.S. Confirmed Malfunctions	0	0.00%
■ Therapy Compromised	0	0.00%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.
Total Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1

## 5.2 Dual-Chamber ICDs

### Ilesto 7 DF4

#### Product Details

Product Versions	DR-T
NBG Code(s)	WE-VDDR
Maximum Energy [J]	40
U.S. Market Release	Jul 2014
CE Market Release	Jun 2013
Worldwide Distributed Devices	3740
Registered U.S. Implants	1 140
Estimated Active U.S. Implants	1 050
U.S. Normal Battery Depletions	0

	Quantity	Rate
U.S. Confirmed Malfunctions	0	0.00%
■ Therapy Compromised	0	0.00%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.
Total Survival [%]	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1




## 5.2 Dual-Chamber ICDs

### Ilesto 7 DX

#### Product Details

Product Versions	VR-T DX
NBG Code(s)	WE-VDDR
Maximum Energy [J]	40
U.S. Market Release	Sep 2013
CE Market Release	Jun 2013
Worldwide Distributed Devices	6 590
Registered U.S. Implants	4 700
Estimated Active U.S. Implants	4 250
U.S. Normal Battery Depletions	2

	Quantity	Rate
U.S. Confirmed Malfunctions	2	0.04%
■ Therapy Compromised	0	0.00%
■ Therapy Available	2	0.04%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.
Total Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1

## 5.2 Dual-Chamber ICDs


### Lexos

#### Product Details

Product Versions*	DR, DR-T, A+, A+/T
NBG Code(s)	DDDRD, VDDR
Maximum Energy [J]	30
U.S. Market Release	Feb 2004
CE Market Release	Oct 2003
Worldwide Distributed Devices	11 700
Registered U.S. Implants	2590
Estimated Active U.S. Implants	497
U.S. Normal Battery Depletions	432

	Quantity	Rate
U.S. Confirmed Malfunctions	6	0.23%
■ Therapy Compromised	2	0.08%
■ Therapy Available	4	0.15%

\* While Lexos A+ and lexos A+/T are not distributed in the U.S., their performance is expected to be similar to the U.S. distributed products



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.
Total Survival [%]	100.0	99.8	99.6	98.1	94.8	84.8	67.9	47.5	26.5	10.8	2.9	0.4
[95% Confidence Interval]		±0.2	±0.3	±0.6	±1.0	±1.8	±2.4	±1.8	±1.0	±0.4	±0.1	
Malfunction-Free Survival [%]	100.0	99.9	99.8	99.8	99.8	99.7	99.6	99.6	99.6	99.6	99.6	99.6
[95% Confidence Interval]		±0.1	±0.2	±0.2	±0.2	±0.2	±0.3	±0.3	±0.3	±0.3	±0.3	±0.3


## 5.2 Dual-Chamber ICDs

### Lumax 340

#### Product Details

Product Versions	DR, DR-T
NBG Code(s)	WE-DDDR
Maximum Energy [J]	40
U.S. Market Release	Feb 2007
CE Market Release	Feb 2007
Worldwide Distributed Devices	26 400
Registered U.S. Implants	8 220
Estimated Active U.S. Implants	2 310
U.S. Normal Battery Depletions	1 731

	Quantity	Rate
U.S. Confirmed Malfunctions	10	0.12%
■ Therapy Compromised	8	0.10%
■ Therapy Available	2	0.02%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.
Total Survival [%]	100.0	99.9	99.7	99.3	97.5	83.2	54.4	18.5	1.3
[95% Confidence Interval]		±0.1	±0.1	±0.2	±0.4	±0.1	±1.2	±0.4	
Malfunction-Free Survival [%]	100.0	100.0	99.9	99.9	99.9	99.8	99.8	99.8	99.8
[95% Confidence Interval]			±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1


## 5.2 Dual-Chamber ICDs

### Lumax 540

#### Product Details

Product Versions	DR-T
NBG Code(s)	WE-DDDR
Maximum Energy [J]	40
U.S. Market Release	May 2009
CE Market Release	Jun 2008
Worldwide Distributed Devices	25 550
Registered U.S. Implants	11 600
Estimated Active U.S. Implants	7760
U.S. Normal Battery Depletions	109

	Quantity	Rate
U.S. Confirmed Malfunctions	12	0.1%
■ Therapy Compromised	7	0.06%
■ Therapy Available	5	0.04%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.
Total Survival [%]	100.0	100.0	100.0	99.9	99.9	99.9	99.8
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0	99.9	99.9	99.9	99.8
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1


## 5.2 Dual-Chamber ICDs

### Lumax 740

#### Product Details

Product Versions	DR-T
NBG Code(s)	WE-DDDR
Maximum Energy [J]	40
U.S. Market Release	Sep 2012
CE Market Release	Apr 2012
Worldwide Distributed Devices	7910
Registered U.S. Implants	3820
Estimated Active U.S. Implants	3140
U.S. Normal Battery Depletions	7

	Quantity	Rate
U.S. Confirmed Malfunctions	1	0.03%
■ Therapy Compromised	0	0.00%
■ Therapy Available	1	0.03%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.
Total Survival [%]	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1


## 5.2 Dual-Chamber ICDs

### Lumax 740 DX

#### Product Details

Product Versions	VR-T DX
NBG Code(s)	WE-VDDR
Maximum Energy [J]	40
U.S. Market Release	May 2012
CE Market Release	Nov 2011
Worldwide Distributed Devices	4 560
Registered U.S. Implants	2 230
Estimated Active U.S. Implants	1 930
U.S. Normal Battery Depletions	0

	Quantity	Rate
U.S. Confirmed Malfunctions	0	0.00%
■ Therapy Compromised	0	0.00%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.
Total Survival [%]	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1


## 5.2 Dual-Chamber ICDs

### Lumos

#### Product Details

Product Versions	DR-T
NBG Code(s)	WE-DDDR
Maximum Energy [J]	30
U.S. Market Release	Sep 2005
CE Market Release	May 2005
Worldwide Distributed Devices	6 600
Registered U.S. Implants	2 240
Estimated Active U.S. Implants	505
U.S. Normal Battery Depletions	385

	Quantity	Rate
U.S. Confirmed Malfunctions	5	0.22%
■ Therapy Compromised	2	0.09%
■ Therapy Available	3	0.13%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.
Total Survival [%]	100.0	99.9	99.6	98.7	96.2	83.0	65.6	41.8	18.4	4.5
[95% Confidence Interval]		±0.2	±0.3	±0.5	±0.9	±2.0	±2.5	±1.7	±0.7	±0.2
Malfunction-Free Survival [%]	100.0	99.9	99.9	99.8	99.8	99.8	99.8	99.8	99.8	99.8
[95% Confidence Interval]		±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2


## 5.3 CRT ICDs

### Ilesto 7

#### Product Details

Product Versions	HF-T
NBG Code(s)	WE-DDDRV
Maximum Energy [J]	40
U.S. Market Release	Sep 2013
CE Market Release	Jun 2013
Worldwide Distributed Devices	6 650
Registered U.S. Implants	3 830
Estimated Active U.S. Implants	3 170
U.S. Normal Battery Depletions	8

	Quantity	Rate
U.S. Confirmed Malfunctions	1	0.03%
■ Therapy Compromised	1	0.03%
■ Therapy Available	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.
Total Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	100.0
[95% Confidence Interval]	±0.1	±0.1	±0.1




## 5.3 CRT ICDs

### Lumax 340

#### Product Details

Product Versions	HF, HF-T
NBG Code(s)	WE-DDDRV
Maximum Energy [J]	40
U.S. Market Release	Feb 2007
CE Market Release	Dec 2006
Worldwide Distributed Devices	20 700
Registered U.S. Implants	5310
Estimated Active U.S. Implants	1070
U.S. Normal Battery Depletions	970

	Quantity	Rate
U.S. Confirmed Malfunctions	4	0.08%
■ Therapy Compromised	2	0.04%
■ Therapy Available	2	0.04%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.
Total Survival [%]	100.0	99.7	99.5	98.6	96.3	88.7	70.9	45.0
[95% Confidence Interval]	±0.1	±0.1	±0.2	±0.4	±0.6	±1.1	±1.8	±2.1
Malfunction-Free Survival [%]	100.0	99.9	99.9	99.9	99.9	99.9	99.9	99.9
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1


## 5.3 CRT ICDs

### Lumax 540

#### Product Details

Product Versions	HF-T
NBG Code(s)	WE-DDDRV
Maximum Energy [J]	40
U.S. Market Release	May 2009
CE Market Release	Jun 2008
Worldwide Distributed Devices	24 400
Registered U.S. Implants	8 660
Estimated Active U.S. Implants	4 210
U.S. Normal Battery Depletions	659

	Quantity	Rate
U.S. Confirmed Malfunctions	11	0.13%
■ Therapy Compromised	5	0.06%
■ Therapy Available	6	0.07%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.
Total Survival [%]	100.0	99.8	99.6	99.0	96.7	86.9
[95% Confidence Interval]		±0.1	±0.1	±0.2	±0.5	±1.2
Malfunction-Free Survival [%]	100.0	100.0	99.9	99.9	99.9	99.8
[95% Confidence Interval]			±0.1	±0.1	±0.1	±0.1


## 5.3 CRT ICDs

### Lumax 740

#### Product Details

Product Versions	HF-T
NBG Code(s)	WE-DDDRV
Maximum Energy [J]	40
U.S. Market Release	Sep 2012
CE Market Release	Apr 2012
Worldwide Distributed Devices	6990
Registered U.S. Implants	3410
Estimated Active U.S. Implants	2490
U.S. Normal Battery Depletions	18

	Quantity	Rate
U.S. Confirmed Malfunctions	2	0.06%
■ Therapy Compromised	0	0.00%
■ Therapy Available	2	0.06%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.
Total Survival [%]	100.0	100.0	99.9	99.9
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1
Malfunction-Free Survival [%]	100.0	100.0	99.9	99.9
[95% Confidence Interval]	±0.1	±0.1	±0.1	±0.1

# 6 Methodology for Lead Survival Estimates Based on Returned Product Analysis and Complaint Information

## 6.1 Cumulative Lead Survival Probability

---

This report has been prepared in accordance with ISO 5841-2:2014(E) applying actuarial analysis for the calculation of lead survival probabilities based on returned product analysis. Lead Survival Estimates given in this report are considered to be generally representative for worldwide performance of BIOTRONIK's pacing and ICD leads.

The Cumulative Survival Probability for leads is an estimate based on the percentage of devices that remain implanted and in service at various points of the product's service time in the absence of concurrent events such as morbidity. The Lead Survival Estimate over time is displayed in cumulative survival curves (Kaplan-Meier). The product's performance is evaluated in discrete one-month intervals. The survival probability for each month is given by the number of leads that remain implanted and active through this month divided by the number of leads that were actively implanted at the start of the interval. The cumulative survival probability for any period is given by multiplying all survival probabilities of previous months.

At the time of implantation, the cumulative lead survival probability is 100 %. Even though they are analyzed as part of our quality system monitoring, leads that are found to be out of specification prior to or during the implantation procedure are removed from the statistics as they do not contribute to a patient's risk of being subject to a device malfunction or replacement during the device's service time. Because this report is provided to communicate information regarding product performance, it does not include data regarding medical complications such as erosion, infection or diaphragmatic stimulation.

Compared to pacemakers and ICDs, a considerable portion of leads with observed or suspected failures are not explanted and returned for laboratory analysis. This is primarily because it is much more difficult and risky to the patient to remove chronically implanted leads. In order to report a conservative measure of lead performance, unconfirmed reports of lead complications are therefore also included in the calculation of a lead's survival probability.

In order to be classified as a qualifying lead complication and thus contributing to the survival probability calculation the same way as a confirmed malfunction, the reported anomaly must have occurred at least 30 days post-implant. Otherwise, factors not related to the lead would likely be the root cause of the observed anomaly, (i.e., patientspecific conditions or implant techniques).

In order to minimize the effect of underreporting of lead malfunctions, BIOTRONIK additionally includes the long term performance post market study data if available.

## 6.2 Lead Data Acquisition

---

The following sections of this report provide performance data on BIOTRONIK's pacing and ICD leads and are based on the observation of BIOTRONIK's U.S. products through review of our device registration and tracking systems, and through the analyses of both, returned leads as well as reports of lead complications of non-returned leads. The prospective data from BIOTRONIK's post-approval studies is presented separately in chapters 8 and 9.

In order to be included in the population under observation a lead must be registered and implanted for at least one calendar day. The cut-off date for the data included in this report is June 30, 2016. The sample sizes of U.S. leads that are implanted and remain active as well as the total number of products distributed worldwide are provided for each lead family in this report.

Survival estimates are calculated for lead families having accumulated at least 10,000 cumulative implant months. Products no longer being distributed with less than 500 active implants may be excluded from this report.

ISO 5841-2:2014(E) describes a method for adjusting the device survival probability for underreported malfunctions and unrelated patient deaths that result in an overestimation of the device's survival probability. The factor for U.S. underreporting of malfunctions of pacing and ICD leads is unknown as currently no systematic data is available that reveals this factor. Consequently, this factor remains unaccounted for in this report. Patient mortality is artificially elevated if the reported rate from our registration and tracking systems is below the annual mortality in clinical studies.

## 6.3 Returned Product Analysis

---

Information for the lead sections of this report is taken from the analysis of returned products. The outcome of this analysis is the basis for the final classification of the cause for explanation of the lead. Additionally, reports of lead complications not confirmed by laboratory analysis are taken into consideration. Both, leads with confirmed malfunctions as well as unconfirmed lead complications decrease a lead's total survival probability.

Every lead and lead segment returned to BIOTRONIK is analyzed per our internal procedures and classified as within specification, damaged by external causes, or out of specification (malfunction) while implanted and in service.

Those leads found to be out of specification, are divided into the following categories as proposed by AdvaMed and ISO 5841-2:2014[E]:

- Conductor Fracture – Conductor break with complete or intermittent loss of continuity that could interrupt current flow (e.g. fractured conductors)
- Crimps, Welds and Bonds – Any interruption in the conductor or lead body associated with a point of connection
- Insulation Breach – Any lead insulation breach
- Other – Includes specific proprietary lead mechanical attributes.

## 6.4 Lead Complications

---

A considerable portion of leads with observed or suspected failures are not explanted and returned for laboratory analysis. A clinical observation is considered a lead complication if a complaint, associated with at least one of the clinical manifestations listed below, is reported and where the non-returned lead is:

- Verified by medical records to have been implanted and in-service, and
- Reported to have been removed from service,
- Modified surgically or electrically to remedy the malfunction, or
- Left in service based on medical judgment.

Complications for leads implanted greater than 30 days are reported as Qualifying lead complications, whereas complications occurring during the first 30 days are reported as Acute Lead Observations.

In accordance with the latest AdvaMed guidelines and ISO 5841-2:2014(E) such clinical observations are classified in the following categories:

- Failure to Capture – Intermittent or complete failure to achieve cardiac stimulation at programmed output delivered outside of the cardiac refractory period. Sudden and significant increase in the pacing threshold value at which 2:1 safety margin can no longer be achieved.
- Failure to Sense – Intermittent or complete loss of sensing or failure to detect intended intrinsic cardiac signals during non-refractory periods at programmed sensitivity settings
- Oversensing – Misinterpretation of cardiac or non-cardiac events as cardiac depolarization
- Abnormal Pacing Impedance – Pacing impedance is typically considered abnormal if a measurement is < 200 ohms or > 3000 ohms
- Abnormal Defibrillation Impedance – Defibrillation impedance is typically considered abnormal if a measurement is < 20 ohms or > 200 ohms. Including high or low shock impedance when attempting to deliver a shock

- Insulation Breach – A disruption or break in lead insulation observed visually, electrically, or radiographically
- Conductor Fracture – A mechanical break within the lead conductor observed visually, electrically, or radiographically
- Lead Dislodgement – Radiographic, electrical or electrocardiographic evidence of electrode displacement from the original implant site or electrode displacement that adversely affects pacing and/or lead performance
- Extracardiac Stimulation – Clinical observation of inadvertent nerve/muscle stimulation other than cardiac muscle
- Cardiac Perforation – Penetration of the lead tip through the myocardium, clinically suspected and confirmed by chest x-ray, fluoroscopy, echocardiogram, or visual observation, which results in clinical symptoms, typically degradation of pacing/ICD lead electrical performance, chest pain, and tamponade
- Other – Specific proprietary attributes of a lead such as sensors which affect a lead's ability to perform as designed or remain in service

In order to report a conservative measure of lead performance, qualifying lead complications are also included in the calculation of a lead's survival probability.

Acute Lead Observations may be subject to a number of factors, including patient-specific anatomy, clinical conditions and/or varying implant conditions/ techniques. Therefore, acute lead observations are not included in lead survival probability.

## 6.5 Lead Product Performance Graphs and Data

---

The lead performance information is shown in each section in alphabetical order and by product name.

For each lead, the report provides:

- Product versions that contribute to the evaluation
- Types of leads
- Polarity
- Steroid
- CE and U.S. market release dates
- Worldwide quantity of products that have been distributed
- U.S. registered implants (number of products included in this report)
- Estimated active U.S. implants
- Number of U.S. qualifying complications
- Number of U.S. acute lead observations
- Number of U.S. confirmed malfunctions
- Number of U.S. leads or partial leads returned post-implant for analysis with a complaint

The survival plots provide:

### **Total Survival**

The cumulative survival probability free of component malfunction or unconfirmed observation of an anomaly. Removals for clinical reasons unrelated to the device's performance (i.e., infections) are excluded.

Products or subgroups of products may become subject to advisory notifications that can significantly impact the overall product performance.

Current advisories are listed in chapter 11 of this report, however to date, BIOTRONIK has never had a pacing or ICD lead safety advisory notification, therefore no summary of lead advisories is provided.

The cumulative survival data and the 95 % confidence intervals according to the Greenwood's formula<sup>1</sup> are shown in numerical form for the observed sample population

<sup>1</sup> Greenwood, M. The Natural Duration of Cancer. Reports on Public Health and Medical Subjects 33, London: Her Majesty's Stationery Office, 1-26, 1926





## 7 Performance of BIOTRONIK Leads Based on Returned Products and Complaint Data

---



---

7.1 Pacing Leads

7.2 ICD Leads

7.3 CRT Leads


# 7.1 Pacing Leads

## Arox

### Product Details

Product Versions	53-BP, 60-BP
Lead Type	straight, passive fixation
Polarity	bipolar
Steroid	no
U.S. Market Release	Sep 2002
CE Market Release	Jan 2002
Worldwide Distributed Devices	36 500
Registered U.S. Implants	8550
Estimated Active U.S. Implants	4580
U.S. Total Returned	19

	Quantity	Rate
U.S. Qualifying Complications	24	0.28%
■ Abnormal pacing impedance	8	0.09%
■ Failure to capture	13	0.15%
■ Insulation breach	2	0.02%
■ Other	1	0.01%
U.S. Confirmed Malfunctions	1	0.01%
■ Insulation breach	1	0.01%
U.S. Acute Lead Observations	2	0.02%
■ Lead dislodgement	2	0.02%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	99.9	99.8	99.7	99.6	99.5	99.5	99.5	99.4
[95% Confidence Interval]							±0.1	±0.1	±0.2	±0.2	±0.2	±0.2	±0.2	±0.3


## 7.1 Pacing Leads

### Arox J

#### Product Details

Product Versions	45-JBP, 53-JBP
Lead Type	J-shape, passive fixation
Polarity	bipolar
Steroid	no
U.S. Market Release	Sep 2002
CE Market Release	Jan 2002
Worldwide Distributed Devices	8760
Registered U.S. Implants	3470
Estimated Active U.S. Implants	2110
U.S. Total Returned	8

	Quantity	Rate
U.S. Qualifying Complications	14	0.40%
■ Abnormal pacing impedance	2	0.06%
■ Failure to capture	9	0.26%
■ Lead dislodgement	2	0.06%
■ Oversensing	1	0.03%
U.S. Confirmed Malfunctions	0	0.00%
U.S. Acute Lead Observations	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.
Total Survival [%]	100.0	100.0	99.9	99.9	99.9	99.8	99.8	99.7	99.6	99.5	99.3	99.3	99.3
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.1	±0.2	±0.2	±0.2	±0.3	±0.3	±0.4	±0.4	±0.4


## 7.1 Pacing Leads

### Dextrus

#### Product Details

Product Versions	4135, 4136, 4137	CE Market Release	May 2007
Lead Type	straight, active fixation	Worldwide Distributed Devices	487 000
Polarity	bipolar	Registered U.S. Implants	378 000
Steroid	yes	Estimated Active U.S. Implants	279 000
U.S. Market Release	Apr 2007	U.S. Total Returned	2015

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	2349	0.62%	U.S. Confirmed Malfunctions	236	0.06%
■ Abnormal pacing impedance	178	0.05%	■ Conductor fracture	88	0.02%
■ Cardiac perforation	23	0.01%	■ Insulation breach	145	0.04%
■ Conductor fracture	52	0.01%	■ Other	3	0.00%
■ Extracardiac stimulation	15	0.00%	U.S. Acute Lead Observations	1418	0.38%
■ Failure to capture	653	0.17%	■ Abnormal pacing impedance	27	0.01%
■ Failure to sense	96	0.03%	■ Cardiac perforation	59	0.02%
■ Insulation breach	47	0.01%	■ Extracardiac stimulation	13	0.00%
■ Lead dislodgement	447	0.12%	■ Failure to capture	193	0.05%
■ Oversensing	389	0.10%	■ Failure to sense	48	0.01%
■ Other	449	0.12%	■ Insulation breach	9	0.00%
			■ Lead dislodgement	572	0.15%
			■ Oversensing	35	0.01%
			■ Other	462	0.12%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.
Total Survival [%]	100.0	99.7	99.5	99.4	99.2	99.1	98.9	98.7	98.5	98.4
[95% Confidence Interval]							±0.1	±0.1	±0.1	±0.1


# 7.1 Pacing Leads

## Elox

### Product Details

Product Versions	45-BP, 53-BP, 60-BP
Lead Type	straight, active fixation
Polarity	bipolar
Steroid	no
U.S. Market Release	May 2000
CE Market Release	May 2000
Worldwide Distributed Devices	36 000
Registered U.S. Implants	11 000
Estimated Active U.S. Implants	3 730
U.S. Total Returned	55

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	58	0.53%	U.S. Confirmed Malfunctions	7	0.06%
■ Abnormal pacing impedance	2	0.02%	■ Conductor fracture	4	0.04%
■ Conductor fracture	2	0.02%	■ Insulation breach	3	0.03%
■ Extracardiac stimulation	1	0.01%	U.S. Acute Lead Observations	8	0.07%
■ Failure to capture	17	0.15%	■ Failure to capture	4	0.04%
■ Failure to sense	11	0.10%	■ Failure to sense	1	0.01%
■ Insulation breach	4	0.04%	■ Oversensing	2	0.02%
■ Lead dislodgement	3	0.03%	■ Other	1	0.01%
■ Oversensing	13	0.12%			
■ Other	5	0.05%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.	14 yr.	15 yr.
Total Survival [%]	100.0	99.8	99.8	99.8	99.8	99.7	99.7	99.6	99.6	99.5	99.4	99.3	99.1	98.9	98.8	98.7
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.2	±0.2	±0.2	±0.2	±0.3	±0.3	±0.3	±0.3


## 7.1 Pacing Leads

### Elox P

#### Product Details

Product Versions	45-BP, 53-BP, 60-BP
Lead Type	straight, active fixation
Polarity	bipolar
Steroid	no
U.S. Market Release	May 2003
CE Market Release	Feb 2003
Worldwide Distributed Devices	21 900
Registered U.S. Implants	3 030
Estimated Active U.S. Implants	1 340
U.S. Total Returned	19

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	15	0.50%	U.S. Confirmed Malfunctions	1	0.03%
■ Abnormal pacing impedance	1	0.03%	■ Insulation breach	1	0.03%
■ Failure to capture	8	0.26%	U.S. Acute Lead Observations	0	0.00%
■ Failure to sense	1	0.03%			
■ Insulation breach	2	0.07%			
■ Lead dislodgement	1	0.03%			
■ Oversensing	1	0.03%			
■ Other	1	0.03%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	99.9	99.8	99.6	99.5	99.4	99.2	99.0	99.0
[95% Confidence Interval]						±0.1	±0.2	±0.3	±0.3	±0.4	±0.4	±0.5	±0.5




# 7.1 Pacing Leads

## Polyrox

### Product Details

Product Versions	60-UP, 53-BP, 53/15-BP, 60-BP, 60/15-BP
Lead Type	straight, passive fixation
Polarity	unipolar/bipolar
Steroid	no
U.S. Market Release	Mar 1997
CE Market Release	Jul 1996
Worldwide Distributed Devices	351 000
Registered U.S. Implants	15 100
Estimated Active U.S. Implants	4 580
U.S. Total Returned	26

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	20	0.13%	U.S. Confirmed Malfunctions	2	0.01%
■ Abnormal pacing impedance	2	0.01%	■ Insulation breach	2	0.01%
■ Conductor fracture	2	0.01%	U.S. Acute Lead Observations	0	0.00%
■ Failure to capture	12	0.08%			
■ Insulation breach	2	0.01%			
■ Lead dislodgement	1	0.01%			
■ Oversensing	1	0.01%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.	14 yr.	15 yr.	16 yr.	17 yr.	18 yr.	
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.9	99.9	99.9	99.8	99.8	99.7	99.7	99.6	99.6	99.5	99.3	
[95% Confidence Interval]									±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.2	±0.2	±0.2	±0.3	±0.5


## 7.1 Pacing Leads

### Polyrox J

#### Product Details

Product Versions	45-JBP, 53-JBP, 53-JUP
Lead Type	J-shape, passive fixation
Polarity	unipolar/bipolar
Steroid	no
U.S. Market Release	Mar 1997
CE Market Release	Jul 1996
Worldwide Distributed Devices	45 900
Registered U.S. Implants	3 740
Estimated Active U.S. Implants	1 210
U.S. Total Returned	6

	Quantity	Rate
U.S. Qualifying Complications	7	0.19%
■ Abnormal pacing impedance	1	0.03%
■ Failure to capture	1	0.03%
■ Failure to sense	2	0.05%
■ Lead dislodgement	1	0.03%
■ Other	2	0.05%
U.S. Confirmed Malfunctions	0	0.00%
U.S. Acute Lead Observations	1	0.03%
■ Failure to capture	1	0.03%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.	14 yr.	15 yr.	16 yr.	17 yr.
Total Survival [%]	100.0	100.0	99.9	99.9	99.9	99.9	99.9	99.8	99.8	99.8	99.8	99.7	99.7	99.7	99.7	99.7	99.7	99.4
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.6


# 7.1 Pacing Leads

## Retrox J

### Product Details

Product Versions	45-JBP, 53-JBP
Lead Type	J-shape, active fixation
Polarity	bipolar
Steroid	no
U.S. Market Release	Aug 1998
CE Market Release	Mar 1997
Worldwide Distributed Devices	14 000
Registered U.S. Implants	4 250
Estimated Active U.S. Implants	1 290
U.S. Total Returned	15

	Quantity	Rate
U.S. Qualifying Complications	17	0.40%
■ Abnormal pacing impedance	2	0.05%
■ Failure to capture	7	0.16%
■ Failure to sense	2	0.05%
■ Lead dislodgement	3	0.07%
■ Oversensing	2	0.05%
■ Other	1	0.02%
U.S. Confirmed Malfunctions	0	0.00%
U.S. Acute Lead Observations	1	0.02%
■ Failure to capture	1	0.02%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.	14 yr.	15 yr.	16 yr.	17 yr.
Total Survival [%]	100.0	99.9	99.9	99.9	99.9	99.8	99.7	99.7	99.7	99.7	99.6	99.6	99.3	99.3	99.2	99.2	99.2	99.0
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.1	±0.1	±0.2	±0.2	±0.2	±0.2	±0.2	±0.3	±0.4	±0.4	±0.4	±0.4	±0.4	±0.5


## 7.1 Pacing Leads

### Selox JT

#### Product Details

Product Versions	45, 53
Lead Type	J-shape, passive fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Nov 2004
CE Market Release	Nov 2004
Worldwide Distributed Devices	140 000
Registered U.S. Implants	15 700
Estimated Active U.S. Implants	12 100
U.S. Total Returned	100

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	138	0.88%	U.S. Confirmed Malfunctions	8	0.05%
■ Abnormal pacing impedance	12	0.08%	■ Insulation breach	8	0.05%
■ Cardiac perforation	1	0.01%	U.S. Acute Lead Observations	37	0.24%
■ Conductor fracture	4	0.03%	■ Failure to capture	5	0.03%
■ Extracardiac stimulation	1	0.01%	■ Lead dislodgement	29	0.19%
■ Failure to capture	61	0.39%	■ Other	3	0.02%
■ Failure to sense	7	0.04%			
■ Insulation breach	7	0.04%			
■ Lead dislodgement	27	0.17%			
■ Oversensing	2	0.01%			
■ Other	16	0.10%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.
Total Survival [%]	100.0	99.8	99.7	99.6	99.3	99.0	98.9	98.6	98.3	98.1	98.1	98.1
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.1	±0.2	±0.2	±0.2	±0.3	±0.4	±0.4	±0.4


## 7.1 Pacing Leads

### Selox SR

#### Product Details

Product Versions	45, 53, 60
Lead Type	straight, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Mar 2004
CE Market Release	Feb 2004
Worldwide Distributed Devices	171 000
Registered U.S. Implants	14 400
Estimated Active U.S. Implants	7 360
U.S. Total Returned	59

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	85	0.59%	U.S. Confirmed Malfunctions	10	0.07%
■ Abnormal pacing impedance	3	0.02%	■ Insulation breach	10	0.07%
■ Conductor fracture	4	0.03%	U.S. Acute Lead Observations	20	0.14%
■ Extracardiac stimulation	2	0.01%	■ Cardiac perforation	1	0.01%
■ Failure to capture	35	0.24%	■ Failure to capture	10	0.07%
■ Failure to sense	1	0.01%	■ Insulation breach	1	0.01%
■ Insulation breach	6	0.04%	■ Lead dislodgement	8	0.06%
■ Lead dislodgement	11	0.08%			
■ Oversensing	10	0.07%			
■ Other	13	0.09%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.
Total Survival [%]	100.0	99.9	99.9	99.8	99.7	99.6	99.5	99.4	99.3	99.2	99.1	99.0	98.9
[95% Confidence Interval]			±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.2	±0.2	±0.2	±0.2	±0.2


## 7.1 Pacing Leads

### Selox ST

#### Product Details

Product Versions	53, 60
Lead Type	straight, passive fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Nov 2004
CE Market Release	Nov 2004
Worldwide Distributed Devices	364 000
Registered U.S. Implants	30 500
Estimated Active U.S. Implants	22 600
U.S. Total Returned	144

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	384	1.26%	U.S. Confirmed Malfunctions	14	0.05%
■ Abnormal pacing impedance	92	0.30%	■ Conductor fracture	1	0.00%
■ Cardiac perforation	3	0.01%	■ Crimps, welds and bonds	1	0.00%
■ Conductor fracture	29	0.10%	■ Insulation breach	12	0.04%
■ Extracardiac stimulation	6	0.02%	U.S. Acute Lead Observations	39	0.13%
■ Failure to capture	185	0.61%	■ Abnormal pacing impedance	1	0.00%
■ Insulation breach	32	0.11%	■ Failure to capture	16	0.05%
■ Lead dislodgement	14	0.05%	■ Lead dislodgement	16	0.05%
■ Oversensing	4	0.01%	■ Other	6	0.02%
■ Other	19	0.06%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.
Total Survival [%]	100.0	99.7	99.6	99.3	99.0	98.6	98.4	98.1	97.8	97.5	97.4	97.3
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.1	±0.2	±0.2	±0.2	±0.2	±0.3	±0.3	±0.3


## 7.1 Pacing Leads

### Setrox S

#### Product Details

Product Versions	45, 53, 60
Lead Type	straight, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Apr 2006
CE Market Release	Mar 2006
Worldwide Distributed Devices	646 000
Registered U.S. Implants	235 000
Estimated Active U.S. Implants	199 000
U.S. Total Returned	1 278

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	808	0.34%	U.S. Confirmed Malfunctions	102	0.04%
■ Abnormal pacing impedance	60	0.03%	■ Conductor fracture	36	0.02%
■ Cardiac perforation	8	0.00%	■ Insulation breach	66	0.03%
■ Conductor fracture	26	0.01%	U.S. Acute Lead Observations	233	0.10%
■ Extracardiac stimulation	6	0.00%	■ Cardiac perforation	18	0.01%
■ Failure to capture	265	0.11%	■ Failure to capture	30	0.01%
■ Failure to sense	22	0.01%	■ Failure to sense	1	0.00%
■ Insulation breach	52	0.02%	■ Insulation breach	4	0.00%
■ Lead dislodgement	211	0.09%	■ Lead dislodgement	167	0.07%
■ Oversensing	76	0.03%	■ Other	13	0.01%
■ Other	82	0.03%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.8	99.7	99.6	99.5	99.3	99.2	99.0	98.9	98.8
[95% Confidence Interval]							±0.1	±0.1	±0.1	±0.1	±0.1


## 7.1 Pacing Leads

### Synox

#### Product Details

Product Versions	60-UP, 53-BP, 60-BP
Lead Type	straight, passive fixation
Polarity	unipolar/bipolar
Steroid	no
U.S. Market Release	Sep 1998
CE Market Release	Jul 1996
Worldwide Distributed Devices	169 000
Registered U.S. Implants	17 600
Estimated Active U.S. Implants	6 260
U.S. Total Returned	57

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	38	0.22%	U.S. Confirmed Malfunctions	5	0.03%
■ Abnormal pacing impedance	3	0.02%	■ Conductor fracture	2	0.01%
■ Conductor fracture	2	0.01%	■ Insulation breach	3	0.02%
■ Extracardiac stimulation	1	0.01%	U.S. Acute Lead Observations	0	0.00%
■ Failure to capture	17	0.10%			
■ Failure to sense	1	0.01%			
■ Insulation breach	6	0.03%			
■ Lead dislodgement	1	0.01%			
■ Oversensing	2	0.01%			
■ Other	5	0.03%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.	14 yr.	15 yr.	16 yr.	17 yr.
Total Survival [%]	100.0	100.0	100.0	100.0	100.0	100.0	99.9	99.9	99.9	99.8	99.7	99.6	99.6	99.5	99.5	99.4	99.4	99.3
[95% Confidence Interval]								±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.2	±0.2	±0.2	±0.2	±0.3




## 7.1 Pacing Leads

### Synox J

#### Product Details

Product Versions	45-JBP, 53-JBP
Lead Type	J-shape, passive fixation
Polarity	bipolar
Steroid	no
U.S. Market Release	Sep 1998
CE Market Release	Jul 1996
Worldwide Distributed Devices	81 400
Registered U.S. Implants	8170
Estimated Active U.S. Implants	3360
U.S. Total Returned	26

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	19	0.23%	U.S. Confirmed Malfunctions	2	0.02%
■ Abnormal pacing impedance	1	0.01%	■ Insulation breach	1	0.01%
■ Conductor fracture	2	0.02%	■ Crimps, welds and bonds	1	0.01%
■ Failure to capture	4	0.05%	U.S. Acute Lead Observations	2	0.02%
■ Failure to sense	4	0.05%	■ Failure to capture	1	0.01%
■ Insulation breach	2	0.02%	■ Oversensing	1	0.01%
■ Lead dislodgement	2	0.02%			
■ Oversensing	3	0.04%			
■ Other	1	0.01%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.	14 yr.	15 yr.	16 yr.	17 yr.	
Total Survival [%]	100.0	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.9	99.8	99.7	99.7	99.6	99.6	99.5	99.5	99.5	99.5	
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.1	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2	±0.2


## 7.1 Pacing Leads

### Tilda JT

#### Product Details

Product Versions	45, 53
Lead Type	J-shape, passive fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Feb 2012
CE Market Release	Sep 2012
Worldwide Distributed Devices	13400
Registered U.S. Implants	691
Estimated Active U.S. Implants	674
U.S. Total Returned	0

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	5	0.72%	U.S. Confirmed Malfunctions	0	0.00%
■ Abnormal pacing impedance	1	0.14%	U.S. Acute Lead Observations	0	0.00%
■ Failure to capture	1	0.14%			
■ Lead dislodgement	3	0.43%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.
Total Survival [%]	100.0	99.5	99.3	99.1
[95% Confidence Interval]		±0.5	±0.7	±0.8


## 7.1 Pacing Leads

### Tilda R

#### Product Details

Product Versions	45, 53, 60
Lead Type	straight, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Dec 2011
CE Market Release	Aug 2011
Worldwide Distributed Devices	37 700
Registered U.S. Implants	8 940
Estimated Active U.S. Implants	8 600
U.S. Total Returned	13

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	23	0.26%	U.S. Confirmed Malfunctions	1	0.01%
■ Abnormal pacing impedance	1	0.01%	■ Conductor fracture	1	0.01%
■ Conductor fracture	3	0.03%	U.S. Acute Lead Observations	8	0.09%
■ Extracardiac stimulation	1	0.01%	■ Lead dislodgement	7	0.08%
■ Failure to capture	6	0.07%	■ Other	1	0.01%
■ Insulation breach	2	0.02%			
■ Lead dislodgement	8	0.09%			
■ Oversensing	1	0.01%			
■ Other	1	0.01%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.
Total Survival [%]	100.0	99.9	99.8	99.7	99.6
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.2


## 7.1 Pacing Leads

### Tilda T

#### Product Details

Product Versions	53, 60
Lead Type	straight, passive fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Dec 2011
CE Market Release	Aug 2011
Worldwide Distributed Devices	18 700
Registered U.S. Implants	1 220
Estimated Active U.S. Implants	1 170
U.S. Total Returned	1

	Quantity	Rate
U.S. Qualifying Complications	5	0.41%
■ Abnormal pacing impedance	1	0.08%
■ Insulation breach	1	0.08%
■ Lead dislodgement	3	0.25%
U.S. Confirmed Malfunctions	0	0.00%
U.S. Acute Lead Observations	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.
Total Survival [%]	100.0	99.7	99.6	99.6
[95% Confidence Interval]		±0.3	±0.4	±0.4




## 7.2 ICD Leads

### Kainox SL

#### Product Details

Product Versions	65, 75, 100
Lead Type	dual-coil, passive fixation
Polarity	bipolar
Steroid	no
U.S. Market Release	Nov 1998
CE Market Release	Sep 1997
Worldwide Distributed Devices	9 600
Registered U.S. Implants	2 500
Estimated Active U.S. Implants	882
U.S. Total Returned	17

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	36	1.44%	U.S. Confirmed Malfunctions	2	0.08%
■ Abnormal defibrillation impedance	1	0.04%	■ Insulation breach	2	0.08%
■ Abnormal pacing impedance	4	0.16%	U.S. Acute Lead Observations	5	0.20%
■ Conductor fracture	3	0.12%	■ Failure to capture	3	0.12%
■ Failure to capture	8	0.32%	■ Failure to sense	1	0.04%
■ Failure to sense	1	0.04%	■ Oversensing	1	0.04%
■ Insulation breach	3	0.12%			
■ Lead dislodgement	1	0.04%			
■ Oversensing	13	0.52%			
■ Other	2	0.08%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.	12 yr.	13 yr.	14 yr.	15 yr.
Total Survival [%]	100.0	99.5	99.4	99.3	99.3	99.3	99.0	99.0	98.8	98.8	98.5	98.2	97.7	97.4	97.2	96.5
[95% Confidence Interval]		±0.3	±0.3	±0.3	±0.3	±0.4	±0.5	±0.5	±0.5	±0.5	±0.6	±0.7	±0.8	±0.9	±1.0	±1.4


## 7.2 ICD Leads

### Kentrox RV

#### Product Details

Product Versions	65, 75, -Steroid
Lead Type	single-coil, passive fixation
Polarity	bipolar
Steroid	yes/no
U.S. Market Release	Mar 2002 / Oct 2004
CE Market Release	Jan 2001 / Dec 2004
Worldwide Distributed Devices	5490
Registered U.S. Implants	409
Estimated Active U.S. Implants	177
U.S. Total Returned	8

	Quantity	Rate
U.S. Qualifying Complications	6	1,47%
■ Conductor fracture	1	0,24%
■ Failure to capture	1	0,24%
■ Insulation breach	1	0,24%
■ Oversensing	3	0,73%
U.S. Confirmed Malfunctions	2	0,49%
■ Conductor fracture	1	0,24%
■ Insulation breach	1	0,24%
U.S. Acute Lead Observations	0	0,00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.
Total Survival [%]	100.0	99.7	99.4	99.4	99.0	98.6	98.2	98.2	98.2
[95% Confidence Interval]		±0.6	±0.8	±0.8	±1.1	±1.3	±1.6	±1.6	±1.6


## 7.2 ICD Leads

### Kentrox SL-S

#### Product Details

Product Versions	65/16, 18 -Steroid
Lead Type	dual-coil, active fixation
Polarity	bipolar
Steroid	yes/no
U.S. Market Release	Oct 2004
CE Market Release	Jun 2004
Worldwide Distributed Devices	8730
Registered U.S. Implants	2440
Estimated Active U.S. Implants	1300
U.S. Total Returned	40

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	40	1.64%	U.S. Confirmed Malfunctions	14	0.57%
■ Abnormal defibrillation impedance	1	0.04%	■ Insulation breach	14	0.57%
■ Abnormal pacing impedance	3	0.12%	U.S. Acute Lead Observations	2	0.08%
■ Conductor fracture	2	0.08%	■ Insulation breach	1	0.04%
■ Failure to capture	2	0.08%	■ Oversensing	1	0.04%
■ Insulation breach	3	0.12%			
■ Lead dislodgement	2	0.08%			
■ Oversensing	25	1.03%			
■ Other	2	0.08%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.	11 yr.
Total Survival [%]	100.0	100.0	99.9	99.7	99.3	99.0	98.2	97.9	97.4	97.3	97.0	96.4
[95% Confidence Interval]			±0.2	±0.3	±0.4	±0.5	±0.6	±0.7	±0.8	±0.8	±0.8	±1.0




## 7.2 ICD Leads

### Kentrox SL

#### Product Details

Product Versions	65, 75, 100, -Steroid
Lead Type	dual coil, passive fixation
Polarity	bipolar
Steroid	yes/no
U.S. Market Release	Oct 2004
CE Market Release	Dec 2003 / Dec 2004
Worldwide Distributed Devices	8480
Registered U.S. Implants	1010
Estimated Active U.S. Implants	547
U.S. Total Returned	19

	Quantity	Rate
U.S. Qualifying Complications	26	2.59%
■ Abnormal pacing impedance	3	0.30%
■ Conductor fracture	2	0.20%
■ Failure to capture	1	0.10%
■ Insulation breach	6	0.60%
■ Oversensing	12	1.19%
■ Other	2	0.20%
U.S. Confirmed Malfunctions	5	0.50%
■ Insulation breach	5	0.50%
U.S. Acute Lead Observations	0	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.	10 yr.
Total Survival [%]	100.0	99.9	99.8	99.4	98.5	98	97.4	96.9	96.9	96.4	95.9
[95% Confidence Interval]		±0.2	±0.3	±0.5	±0.9	±1.0	±1.2	±1.3	±1.3	±1.4	±1.5


## 7.2 ICD Leads

### Linux S

#### Product Details

Product Versions	65, 75
Lead Type	single-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Feb 2007
CE Market Release	Mar 2007
Worldwide Distributed Devices	31 900
Registered U.S. Implants	2500
Estimated Active U.S. Implants	1810
U.S. Total Returned	59

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	48	1.93%	U.S. Confirmed Malfunctions	27	1.08%
■ Abnormal defibrillation impedance	6	0.24%	■ Conductor fracture	4	0.16%
■ Abnormal pacing impedance	3	0.12%	■ Insulation breach	23	0.92%
■ Conductor fracture	3	0.12%	U.S. Acute Lead Observations	2	0.08%
■ Failure to capture	5	0.20%	■ Lead dislodgement	1	0.04%
■ Insulation breach	3	0.12%	■ Other	1	0.04%
■ Oversensing	22	0.88%			
■ Other	6	0.24%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.
Total Survival [%]	100.0	99.8	99.2	98.8	98.0	97.1	96.3	95.6	95.6
[95% Confidence Interval]		±0.2	±0.4	±0.5	±0.6	±0.7	±0.9	±1.0	±1.0


## 7.2 ICD Leads

### Linux SD

#### Product Details

Product Versions	60, 65, 75 / 16,18
Lead Type	dual-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Apr 2006
CE Market Release	Jun 2005
Worldwide Distributed Devices	55 100
Registered U.S. Implants	22 300
Estimated Active U.S. Implants	15 400
U.S. Total Returned	423

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	501	2.25%	U.S. Confirmed Malfunctions	165	0.74%
■ Abnormal defibrillation impedance	32	0.14%	■ Conductor fracture	22	0.10%
■ Abnormal pacing impedance	38	0.17%	■ Insulation breach	142	0.64%
■ Cardiac perforation	2	0.01%	■ Other	1	0.00%
■ Conductor fracture	38	0.17%	U.S. Acute Lead Observations	11	0.05%
■ Failure to capture	48	0.22%	■ Abnormal pacing impedance	1	0.00%
■ Failure to sense	4	0.02%	■ Cardiac perforation	1	0.00%
■ Insulation breach	50	0.22%	■ Failure to capture	1	0.00%
■ Lead dislodgement	31	0.14%	■ Lead dislodgement	6	0.03%
■ Oversensing	215	0.97%	■ Oversensing	1	0.00%
■ Other	43	0.19%	■ Other	1	0.00%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.
Total Survival [%]	100.0	99.7	99.4	98.9	98.4	97.7	97.0	96.2	95.5	95.2
[95% Confidence Interval]		±0.1	±0.1	±0.1	±0.2	±0.2	±0.3	±0.3	±0.4	±0.4


## 7.2 ICD Leads

### Linux<sup>smart</sup> S

#### Product Details

Product Versions	60, 65, 75
Lead Type	single-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Aug 2011
CE Market Release	Dec 2010
Worldwide Distributed Devices	45 600
Registered U.S. Implants	7 300
Estimated Active U.S. Implants	6 480
U.S. Total Returned	109

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	48	0.66%	U.S. Confirmed Malfunctions	23	0.32%
■ Abnormal defibrillation impedance	3	0.04%	■ Conductor fracture	3	0.04%
■ Abnormal pacing impedance	2	0.03%	■ Insulation breach	20	0.27%
■ Cardiac perforation	1	0.01%	U.S. Acute Lead Observations	11	0.15%
■ Conductor fracture	2	0.03%	■ Abnormal pacing impedance	1	0.01%
■ Failure to capture	7	0.10%	■ Cardiac perforation	1	0.01%
■ Failure to sense	2	0.03%	■ Lead dislodgement	8	0.11%
■ Insulation breach	1	0.01%	■ Other	1	0.01%
■ Lead dislodgement	12	0.16%			
■ Oversensing	15	0.21%			
■ Other	3	0.04%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.
Total Survival [%]	100.0	99.7	99.4	99.0	98.3
[95% Confidence Interval]		±0.1	±0.2	±0.3	±0.4


## 7.2 ICD Leads

### Linux<sup>smart</sup> S DX

#### Product Details

Product Versions	65/15, 65/17
Lead Type	single-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Feb 2013
CE Market Release	Mar 2010
Worldwide Distributed Devices	31 100
Registered U.S. Implants	11 400
Estimated Active U.S. Implants	10 700
U.S. Total Returned	140

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	29	0.26%	U.S. Confirmed Malfunctions	20	0.18%
■ Abnormal defibrillation impedance	1	0.01%	■ Conductor fracture	2	0.02%
■ Conductor fracture	1	0.01%	■ Insulation breach	18	0.16%
■ Failure to capture	1	0.01%	U.S. Acute Lead Observations	25	0.22%
■ Failure to sense	1	0.01%	■ Cardiac perforation	3	0.03%
■ Lead dislodgement	18	0.16%	■ Failure to capture	4	0.04%
■ Oversensing	5	0.04%	■ Lead dislodgement	13	0.11%
■ Other	2	0.02%	■ Other	5	0.04%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.
Total Survival [%]	100.0	99.7	99.5	99.0
[95% Confidence Interval]		±0.1	±0.2	±0.4


## 7.2 ICD Leads

### Linix<sup>smart</sup> SD

#### Product Details

Product Versions	60/16, 65/16, 65/18, 75/18
Lead Type	dual-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Jan 2011
CE Market Release	Oct 2009
Worldwide Distributed Devices	52800
Registered U.S. Implants	12900
Estimated Active U.S. Implants	11200
U.S. Total Returned	177

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	93	0.72%	U.S. Confirmed Malfunctions	31	0.24%
■ Abnormal defibrillation impedance	6	0.05%	■ Conductor fracture	3	0.02%
■ Abnormal pacing impedance	4	0.03%	■ Insulation breach	28	0.22%
■ Conductor fracture	11	0.09%	U.S. Acute Lead Observations	29	0.23%
■ Failure to capture	9	0.07%	■ Abnormal defibrillation impedance	1	0.01%
■ Failure to sense	1	0.01%	■ Cardiac perforation	2	0.02%
■ Insulation breach	6	0.05%	■ Failure to capture	4	0.03%
■ Lead dislodgement	14	0.11%	■ Insulation breach	1	0.01%
■ Oversensing	36	0.28%	■ Lead dislodgement	12	0.09%
■ Other	6	0.05%	■ Oversensing	2	0.02%
			■ Other	7	0.05%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.
Total Survival [%]	100.0	99.7	99.5	99.3	98.7	98.3
[95% Confidence Interval]		±0.1	±0.1	±0.2	±0.2	±0.4


## 7.2 ICD Leads

### Linux<sup>smart</sup> TD

#### Product Details

Product Versions	65/16, 65/18, 75/18
Lead Type	dual-coil, passive fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Jan 2011
CE Market Release	Oct 2009
Worldwide Distributed Devices	7610
Registered U.S. Implants	1260
Estimated Active U.S. Implants	1090
U.S. Total Returned	17

	Quantity	Rate
U.S. Qualifying Complications	13	1.03%
■ Abnormal defibrillation impedance	1	0.08%
■ Abnormal pacing impedance	1	0.08%
■ Conductor fracture	1	0.08%
■ Failure to capture	2	0.16%
■ Insulation breach	2	0.16%
■ Lead dislodgement	4	0.32%
■ Oversensing	2	0.16%
U.S. Confirmed Malfunctions	0	0.00%
U.S. Acute Lead Observations	3	0.24%
■ Lead dislodgement	3	0.24%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.
Total Survival [%]	100.0	99.6	99.3	98.9	98.8
[95% Confidence Interval]		±0.4	±0.5	±0.6	±0.7


## 7.2 ICD Leads

### Linux T

#### Product Details

Product Versions	65, 75
Lead Type	single-coil, passive fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Feb 2007
CE Market Release	Mar 2007
Worldwide Distributed Devices	2280
Registered U.S. Implants	322
Estimated Active U.S. Implants	232
U.S. Total Returned	3

	Quantity	Rate
U.S. Qualifying Complications	12	3.73%
■ Abnormal pacing impedance	1	0.31%
■ Failure to capture	3	0.93%
■ Insulation breach	1	0.31%
■ Oversensing	6	1.86%
■ Other	1	0.31%
U.S. Confirmed Malfunctions	2	0.62%
■ Insulation breach	2	0.62%
U.S. Acute Lead Observations	1	0.31%
■ Other	1	0.31%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.
Total Survival [%]	100.0	100.0	99.3	99.0	97.1	96.3	95.4
[95% Confidence Interval]			±0.9	±1.2	±2.0	±2.3	±2.6




## 7.2 ICD Leads

### Linux TD

#### Product Details

Product Versions	65, 75, 100/16, 100/18
Lead Type	dual-coil, passive fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Oct 2006
CE Market Release	Oct 2006
Worldwide Distributed Devices	14 600
Registered U.S. Implants	3060
Estimated Active U.S. Implants	2 130
U.S. Total Returned	69

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	85	2.79%	U.S. Confirmed Malfunctions	33	1.08%
■ Abnormal defibrillation impedance	8	0.26%	■ Conductor fracture	6	0.20%
■ Abnormal pacing impedance	9	0.29%	■ Insulation breach	27	0.88%
■ Conductor fracture	8	0.26%	U.S. Acute Lead Observations	3	0.10%
■ Failure to capture	13	0.43%	■ Failure to capture	1	0.03%
■ Failure to sense	2	0.07%	■ Lead dislodgement	2	0.07%
■ Insulation breach	13	0.43%			
■ Lead dislodgement	4	0.13%			
■ Oversensing	26	0.85%			
■ Other	2	0.07%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.
Total Survival [%]	100.0	99.5	99.2	98.6	97.8	96.6	95.6	94.9	94.4
[95% Confidence Interval]		±0.3	±0.3	±0.4	±0.6	±0.7	±0.8	±0.9	±1.0


## 7.2 ICD Leads

### Protego S

#### Product Details

Product Versions	60, 65, 75
Lead Type	single-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Jul 2014
CE Market Release	Feb 2014
Worldwide Distributed Devices	33 700
Registered U.S. Implants	4 080
Estimated Active U.S. Implants	3 850
U.S. Total Returned	25

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	14	0.34%	U.S. Acute Lead Observations	14	0.34%
■ Cardiac perforation	1	0.02%	■ Cardiac perforation	1	0.02%
■ Failure to capture	2	0.05%	■ Extracardiac stimulation	1	0.02%
■ Lead dislodgement	8	0.20%	■ Failure to capture	1	0.02%
■ Oversensing	1	0.02%	■ Lead dislodgement	7	0.17%
■ Other	2	0.05%	■ Other	4	0.10%
U.S. Confirmed Malfunctions	2	0.05%			
■ Conductor fracture	1	0.02%			
■ Insulation breach	1	0.02%			



Cumulative Survival Probability after	Impl.	1 yr.
Total Survival [%]	100.0	99.4
[95% Confidence Interval]		±0.3


## 7.2 ICD Leads

### Protego SD

#### Product Details

Product Versions	60/16, 65/16, 65/18, 75/18
Lead Type	dual-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Jul 2014
CE Market Release	May 2013
Worldwide Distributed Devices	14 700
Registered U.S. Implants	2040
Estimated Active U.S. Implants	1940
U.S. Total Returned	13

	Quantity	Rate
U.S. Qualifying Complications	2	0.10%
■ Lead dislodgement	2	0.10%
U.S. Confirmed Malfunctions	0	0.00%
U.S. Acute Lead Observations	2	0.10%
■ Lead dislodgement	2	0.10%



Cumulative Survival Probability after	Impl.	1 yr.
Total Survival [%]	100.0	99.9
[95% Confidence Interval]		±0.2


## 7.2 ICD Leads

### Vigila 2CR

#### Product Details

Product Versions	60/16, 65/18
Lead Type	dual-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Feb 2012
CE Market Release	Oct 2011
Worldwide Distributed Devices	3010
Registered U.S. Implants	799
Estimated Active U.S. Implants	735
U.S. Total Returned	10

	Quantity	Rate
U.S. Qualifying Complications	9	1.13%
■ Conductor fracture	1	0.13%
■ Lead dislodgement	3	0.38%
■ Oversensing	5	0.63%
U.S. Confirmed Malfunctions	3	0.38%
■ Insulation breach	3	0.38%
U.S. Acute Lead Observations	1	0.13%
■ Other	1	0.13%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.
Total Survival [%]	100.0	99.9	99.3	98.5
[95% Confidence Interval]		±0.3	±0.6	±0.9


## 7.3 CRT Leads

### Corox

#### Product Details

Product Versions	OTW-L 75-BP, 85-BP
Lead Type	dual-curve fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Jan 2011
CE Market Release	Dec 2009
Worldwide Distributed Devices	29300
Registered U.S. Implants	5500
Estimated Active U.S. Implants	4710
U.S. Total Returned	52

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	54	0.98%	U.S. Confirmed Malfunctions	2	0.04%
■ Conductor fracture	2	0.04%	■ Conductor fracture	1	0.02%
■ Extracardiac stimulation	12	0.22%	■ Insulation breach	1	0.02%
■ Failure to capture	18	0.33%	U.S. Acute Lead Observations	20	0.36%
■ Lead dislodgement	19	0.35%	■ Extracardiac stimulation	6	0.11%
■ Other	3	0.05%	■ Failure to capture	2	0.04%
			■ Lead dislodgement	9	0.16%
			■ Other	3	0.05%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.
Total Survival [%]	100.0	99.2	99.0	98.8	98.5	98.3
[95% Confidence Interval]		±0.2	±0.3	±0.3	±0.4	±0.6


## 7.3 CRT Leads

### Corox

#### Product Details

Product Versions	OTW-S 75-BP, 85-BP
Lead Type	thread fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	May 2008
CE Market Release	Dec 2006
Worldwide Distributed Devices	25300
Registered U.S. Implants	7690
Estimated Active U.S. Implants	5640
U.S. Total Returned	106

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	91	1.18%	U.S. Confirmed Malfunctions	10	0.13%
■ Abnormal pacing impedance	2	0.03%	■ Conductor fracture	5	0.07%
■ Conductor fracture	1	0.01%	■ Insulation breach	4	0.05%
■ Extracardiac stimulation	8	0.10%	■ Other	1	0.01%
■ Failure to capture	21	0.27%	U.S. Acute Lead Observations	26	0.34%
■ Insulation breach	4	0.05%	■ Cardiac perforation	1	0.01%
■ Lead dislodgement	40	0.52%	■ Extracardiac stimulation	3	0.04%
■ Oversensing	1	0.01%	■ Failure to capture	5	0.07%
■ Other	14	0.18%	■ Lead dislodgement	16	0.21%
			■ Other	1	0.01%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.
Total Survival [%]	100.0	99.4	99.1	98.9	98.6	98.2	97.9	97.5
[95% Confidence Interval]		±0.2	±0.2	±0.3	±0.3	±0.4	±0.5	±0.6


## 7.3 CRT Leads

### Corox

#### Product Details

Product Versions	OTW 75-BP Steroid, 85-BP Steroid
Lead Type	helix fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	May 2008
CE Market Release	Dec 2006
Worldwide Distributed Devices	27 400
Registered U.S. Implants	4 050
Estimated Active U.S. Implants	2 750
U.S. Total Returned	68

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	77	1.90%	U.S. Confirmed Malfunctions	16	0.40%
■ Abnormal pacing impedance	2	0.05%	■ Conductor fracture	15	0.37%
■ Conductor fracture	2	0.05%	■ Insulation breach	1	0.02%
■ Extracardiac stimulation	6	0.15%	U.S. Acute Lead Observations	8	0.20%
■ Failure to capture	26	0.64%	■ Lead dislodgement	6	0.15%
■ Insulation breach	2	0.05%	■ Other	2	0.05%
■ Lead dislodgement	29	0.72%			
■ Oversensing	2	0.05%			
■ Other	8	0.20%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.
Total Survival [%]	100.0	99.5	98.8	98.3	97.9	97.2	96.7	96.1
[95% Confidence Interval]		±0.2	±0.4	±0.5	±0.5	±0.6	±0.7	±0.8


## 7.3 CRT Leads

### Corox

#### Product Details

Product Versions	OTW 75-UP Steroid, 85-UP Steroid
Lead Type	helix fixation
Polarity	unipolar
Steroid	yes
U.S. Market Release	Aug 2006
CE Market Release	Apr 2004
Worldwide Distributed Devices	10 400
Registered U.S. Implants	1 430
Estimated Active U.S. Implants	721
U.S. Total Returned	25

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	26	1.82%	U.S. Confirmed Malfunctions	1	0.07%
■ Extracardiac stimulation	4	0.28%	■ Insulation breach	1	0.07%
■ Failure to capture	5	0.35%	U.S. Acute Lead Observations	3	0.21%
■ Insulation breach	2	0.14%	■ Failure to capture	2	0.14%
■ Lead dislodgement	9	0.63%	■ Lead dislodgement	1	0.07%
■ Oversensing	1	0.07%			
■ Other	5	0.35%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.	6 yr.	7 yr.	8 yr.	9 yr.
Total Survival [%]	100.0	99.8	99.7	99.4	99.1	98.7	98.3	97.7	97.4	97.0
[95% Confidence Interval]		±0.3	±0.3	±0.5	±0.6	±0.7	±0.8	±1.0	±1.0	±1.2





# 8 Methodology for Lead Survival Estimates Based on Clinical Studies

## 8.1 Introduction

---

All leads and lead segments returned to BIOTRONIK are thoroughly analyzed to determine whether or not they meet BIOTRONIK's long term quality standards. Although analysis of returned product is an excellent method for gaining insight into lead failure mechanisms, this data relies on the return of explanted leads. For the majority of complications the lead is not received for analysis as challenging clinical environments may not allow for the return, e.g. the extraction of an implanted lead may not be possible.

BIOTRONIK includes all reported chronic complications in the calculation of the survival estimates as described in chapter 6, i.e. reports with returned and without returned products.

However, BIOTRONIK can only report events in the survival estimates if those events were reported to BIOTRONIK. In order to eliminate possible biased survival estimates due to underreporting, BIOTRONIK performs clinical surveillance studies with active follow-up's under FDA guidance yielding the most reliable lead performance data.

In the following chapter BIOTRONIK shows – in addition to the survival data based on returned product analysis and chronic complication information – the lead performance data from clinical trials. These studies are designed to record clinical observations representative of the total clinical experience.

## 8.2 BIOTRONIK's Clinical Studies

---

### 8.2.1 GALAXY and CELESTIAL

BIOTRONIK's GALAXY and CELESTIAL Registries are prospective, non-randomized, observational studies. The key purpose of these registries is to confirm the long-term safety and reliability of BIOTRONIK leads as used in conjunction with a BIOTRONIK ICD (GALAXY) or CRT (CELESTIAL) system. All devices in the registries are legally marketed and available to physicians according to approved FDA indications for use. GALAXY and CELESTIAL Registries are registered on clinicaltrials.gov under NCT00836589 and NCT00810264 respectively.

The evaluation of safety for GALAXY is based on the analysis of BIOTRONIK Linx ICD lead-related adverse events. The evaluation of safety for CELESTIAL is based on the analysis of BIOTRONIK Corox LV pacing lead-related adverse events. However, many CELESTIAL patients also have a Linx ICD lead implanted and the Linx clinical studies data in this report represents combined data from the GALAXY and CELESTIAL registries. Both registries are designed to continue for a 5 year follow-up duration per patient. To ensure a sufficiently large and representative source of data, participating clinical sites must meet pre-specified selection criteria.

Every effort is made to ensure participants are representative of the range of clinical environments in which BIOTRONIK's cardiac rhythm products are used. Patients will be seen for routine follow-up visits per their institutional standard of care until they can no longer be followed (e.g., death, lost to follow-up, etc.). However, to ensure regular patient status assessments are completed, follow-up windows consistent with typical care practices have been established with a minimum of once every six months follow-up requirement.

During each follow up at a study center the following steps are required during the follow-up visit:

- Interrogate programmed parameters
- Determine lead electrical parameters
- Evaluate device diagnostics and programmed parameters to ensure the device is providing appropriate therapy
- Determine if there are any reportable lead-related, pulse generator-related or implant procedure-related adverse events. If there are, complete an adverse event electronic case report form (eCRF)
- Complete all appropriate eCRFs

This active surveillance model ensures a robust dataset for effectively monitoring product performance.

### Patient Enrolment Criteria

To support the objectives of these registries, participants are required to meet the following inclusion criteria prior to enrolment:

- Successfully implanted BIOTRONIK ICD (GALAXY) or BIOTRONIK CRT (CELESTIAL) system, including the study lead
- Able to understand the nature of the registry and give informed consent
- Available for follow-up visits on a regular basis at the study site
- Age greater than or equal to 18 years

Each site must inform BIOTRONIK whenever a lead complication has occurred or when a patient is no longer participating.

All leads that experience a complication and are subsequently explanted and returned to BIOTRONIK undergo root-cause analyses. Product performance is analyzed as a function of time using the survival analysis method. Root causes for any failures, regardless of the incidence rates, are investigated.

## 8.2 BIOTRONIK's Clinical Studies

---

### 8.2.2 SIELLO Clinical Study

BIOTRONIK's SIELLO Clinical Study is a prospective, non-randomized, combined Pre-Market Study and Post-Approval Registry designed to demonstrate the safety and effectiveness of the Siello pacing lead as used in conjunction with any market-released BIOTRONIK pacemaker device. The SIELLO Clinical Study is registered on clinicaltrials.gov under NCT01791127.

For the Pre-Market Study, the evaluation of safety is based on the analysis of Siello lead-related adverse events through a follow-up time of 12 months post-implant, while the evaluation of effectiveness is based on analysis of the success rate of the implanted system including one or two Siello leads to sense and deliver pacing at 12 months post-implant. For the Post-Approval Registry, the evaluation of long-term safety is based on the analysis of Siello lead-related adverse events through a follow-up time of 5 years post-implant. To ensure a sufficiently large and representative source of data, participating clinical sites must meet pre-specified selection criteria.

Every effort is made to ensure participants are representative of the range of clinical environments in which BIOTRONIK's cardiac rhythm products are used. Patients will be seen for routine follow-up visits until they can no longer be followed (e.g., death, lost to follow-up, etc.). However, to ensure regular patient status assessments are completed, a study follow-up schedule consistent with typical care practices has been established, with required follow-ups at 3 and 6 months post-implant and every 6 months thereafter.

During each follow up at a study center the following steps are required during the follow-up visit:

- Interrogate programmed parameters
- Record electrical parameters of the implanted leads. Perform all pacing threshold measurements at 0.4 ms or 0.5 ms pulse width when feasible
- Evaluate device diagnostics, electrical parameters and programmed parameters to ensure the device is correctly pacing and sensing
- Determine if there are any lead-related, pulse generator-related or procedure related adverse events. If any are recorded, complete the Adverse Event eCRF
- Complete all appropriate eCRFs

This active surveillance model ensures a robust dataset for effectively monitoring product performance.

### Patient Enrolment Criteria

To support the objectives of the study, participants are required to meet the following inclusion criteria prior to enrollment:

- Candidate for de novo implantation of a market-released BIOTRONIK pacemaker system, including one or two Siello leads. Candidate meets recommendation for pacemaker system implant put forth by guidelines of relevant professional societies
- Able to understand the nature of the study and provide informed consent
- Available for follow-up visits on a regular basis at the investigational site for the expected 5 years of follow-up
- Age greater than or equal to 18 years

Each site must inform BIOTRONIK whenever a lead complication has occurred or when a patient is no longer participating.

All leads that experience a complication and are subsequently explanted and returned to BIOTRONIK undergo root-cause analyses. Product performance is analyzed as a function of time using the survival analysis method. Root causes for any failures, regardless of the incidence rates, are investigated.

## 8.2 BIOTRONIK's Clinical Studies

---

### 8.2.3 Protego Post-Approval Registry

BIOTRONIK's Protego Post-Approval Registry is a prospective, single-arm, non-randomized registry to confirm the long-term safety and reliability of the Protego DF4 ICD lead when used in conjunction with a BIOTRONIK DF4 compatible ICD or CRT-D pulse generator. The Protego DF4 Post-Approval Registry is registered on clinicaltrials.gov under NCT02243696.

The evaluation of safety will be based on the analysis of Protego DF4 lead related or header related adverse events through a follow-up time of 5 years post-implant. To ensure a sufficiently large and representative source of data, participating clinical sites must meet pre-specified selection criteria.

Every effort is made to ensure participants are representative of the range of clinical environments in which BIOTRONIK's cardiac rhythm products are used. Patients will be seen for routine follow-up visits per their institutional standard of care until they can no longer be followed (e.g., death, lost to follow-up, etc.). However, to ensure regular patient status assessments are completed, a study follow-up schedule consistent with typical care practices has been established, with required follow-ups at 3 and 6 months post-implant, and every 6 months thereafter.

During each study visit, the following are required:

- Interrogate programmed parameters
- Record electrical parameters of the implanted leads. Perform all pacing threshold measurements at 0.4 ms or 0.5 ms pulse width when feasible
- Evaluate device diagnostics and programmed parameters to ensure the device is providing appropriate therapy
- Determine if there are any lead-related, pulse generator-related or procedure related adverse events. If any are recorded, complete the Adverse Event eCRF
- Complete all appropriate eCRFs

This active surveillance model ensures a robust dataset for effectively monitoring product performance.

### Patient Enrolment Criteria

To support the objectives of the study, participants are required to meet the following inclusion criteria prior to enrollment:

- Candidate for implant or successfully implanted with a BIOTRONIK ICD or BIOTRONIK CRT-D system, including a Protego lead
- Able to understand the nature of the registry and give informed consent
- Available for follow-up visits on a regular basis at the study site
- Age greater than or equal to 18 years

Each site must inform BIOTRONIK whenever a lead complication has occurred or when a patient is no longer participating.

All leads that experience a complication and are subsequently explanted and returned to BIOTRONIK undergo root-cause analyses. Product performance is analyzed as a function of time using the survival analysis method. Root causes for any failures, regardless of the incidence rates, are investigated.

## 8.3 Lead Complications

---

The data presented characterizes chronic lead performance by estimating lead-related complication free survival probabilities. Following industry practice, for analysis purposes, the complication criteria, which align with the AdvaMed 'Industry Guidance for Uniform Reporting of Clinical Performance of Cardiac Rhythm Management Pulse Generators and Leads', are defined below.

### 8.3.1 GALAXY and CELESTIAL

All reported lead-related adverse events within the GALAXY and CELESTIAL Registries are classified by the reporting investigator and are adjudicated by an independent event adjudication committee. A lead related complication is considered to have occurred if a clinical observation happens after successful implantation, is classified with at least one of the following event classifications and at least one of the following clinical actions is made. Any Clinical Event without a related Clinical Action is not considered a Qualifying Complication. Events with an onset date 30 days or less after the implant are acute observations and are listed separately.

#### Event Classifications

- Failure to capture
- Failure to sense/undersensing
- Oversensing
- Abnormal pacing impedance (based on lead model, but normal range is typically 200–2,000 ohms)
- Abnormal defibrillation impedance (based on lead model, but normal range is 25–150 ohms)
- Insulation breach
- Conductor fracture, confirmed electrically, visually or radiographically
- Extracardiac stimulation
- Cardiac perforation
- Lead dislodgement

#### Clinical Actions

- Lead surgically abandoned/capped
- Lead electrically abandoned
- Lead explanted
- Lead replaced
- Lead conductor taken out of service
- Lead use continued based on medical judgment despite a known clinical performance issue
- Other lead-related surgery

## 8.3 Lead Complications

---

### 8.3.2 SIELLO

All reported lead-related adverse events within the SIELLO Clinical Study are classified by the reporting investigator and are adjudicated by an independent event adjudication committee. A lead related complication is considered to have occurred if a clinical observation happens after successful implantation and is classified with at least one of the following event classifications. Events with an onset date 30 days or less after the implant are acute observations and are listed separately.

#### Event Classifications

- Failure to capture
- Failure to sense/undersensing
- Oversensing
- Abnormal pacing impedance (based on lead model, but normal range is typically 200–2,000 ohms)
- Insulation breach
- Conductor fracture, confirmed electrically, visually or radiographically
- Extracardiac stimulation
- Cardiac perforation
- Lead dislodgement

### 8.3.3 Protego

All reported lead-related adverse events within the Protego Registry are classified by the reporting investigator and are adjudicated by an independent event adjudication committee. A lead related complication is considered to have occurred if a clinical observation happens after successful implantation and is classified with at least one of the following event classifications. Events with an onset date 30 days or less after the implant are acute observations and are listed separately.

- Failure to capture
- Failure to sense/undersensing
- Oversensing
- Abnormal pacing impedance (based on lead model, but normal range is typically 200–2,000 ohms)
- Abnormal defibrillation impedance (based on lead model, but normal range is 25–150 ohms)
- Insulation breach
- Conductor fracture, confirmed electrically, visually or radiographically
- Extracardiac stimulation
- Cardiac perforation

## 8.4 Lead Product Performance Graphs and Data

---

The clinical data presented on the following page is intended to show the long term clinical performance of leads based on clinical studies. The same analysis methods as described in chapter 6 are applied.

### **Returned Product Analysis Results**

Although the returned product analysis data is not used to generate the survival estimates for the clinical data, it provides valuable insight into the causes of lead malfunction. Following the same approach as for complaint data, a malfunction is reported as described in section 6.3 of this report.





## 9 Performance of BIOTRONIK Leads Based on Clinical Studies

---



- 
- 9.1 Performance of Pacing Leads
  - 9.2 Performance of ICD Leads
  - 9.3 Performance of CRT Leads


## 9.1 Performance of Pacing Leads

### Siello S/Solia S Study Data

#### Product Details

Product Versions	45, 53, 60
Lead Type	straight, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Jun 2016
CE Market Release	Jul 2009
Worldwide Distributed Devices	580 000
Registered U.S. Implants	3 235

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	34	1.05%	U.S. Confirmed Malfunctions	2	0.06%
■ Cardiac perforation	1	0.03%	■ Conductor fracture	1	0.03%
■ Failure to capture	15	0.46%	■ Insulation breach	1	0.03%
■ Failure to sense (undersensing)	8	0.25%	U.S. Acute Lead Observations	26	0.80%
■ Lead dislodgement	8	0.25%	■ Cardiac perforation	8	0.25%
■ Oversensing	1	0.03%	■ Extracardiac stimulation	2	0.06%
■ Other	1	0.03%	■ Failure to capture	6	0.19%
			■ Failure to sense (undersensing)	5	0.15%
			■ Lead dislodgement	5	0.15%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.
Total Survival [%]	100.0	99.0	98.9	98.8
[95% Confidence Interval]		±0.4	±0.4	±0.4


## 9.2 Performance of ICD Leads

### Linux SD Study Data

#### Product Details

Product Versions	60, 65, 75/16, 18
Lead Type	dual-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Apr 2006
U.S. Study Begin	Aug 2008
Worldwide Distributed Devices	55 100
Registered U.S. Implants	2271

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	62	2.73%	U.S. Confirmed Malfunctions	20	0.88%
■ Abnormal defibrillation impedance	4	0.18%	■ Conductor fracture	3	0.13%
■ Abnormal pacing impedance	9	0.40%	■ Insulation breach	17	0.75%
■ Cardiac perforation	1	0.04%	U.S. Acute Lead Observations	9	0.40%
■ Conductor fracture	8	0.35%	■ Cardiac perforation	4	0.18%
■ Failure to capture	7	0.31%	■ Failure to capture	2	0.09%
■ Failure to sense (undersensing)	3	0.13%	■ Insulation breach	1	0.04%
■ Insulation breach	7	0.31%	■ Lead dislodgement	1	0.04%
■ Lead dislodgement	3	0.13%	■ Other	1	0.04%
■ Oversensing	20	0.88%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.
Total Survival [%]	100.0	99.6	98.8	98.2	96.8	95.5
[95% Confidence Interval]		±0.3	±0.5	±0.7	±0.9	±1.2


## 9.2 Performance of ICD Leads

### Linux<sup>smart</sup> SD Study Data

#### Product Details

Product Versions	60/16, 65/16, 65/18, 75/18
Lead Type	dual-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Jan 2011
CE Market Release	Oct 2009
Worldwide Distributed Devices	52800
Registered U.S. Implants	734

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	24	3.27%	U.S. Confirmed Malfunctions	7	0.95%
■ Abnormal defibrillation impedance	2	0.27%	■ Insulation breach	7	0.95%
■ Abnormal pacing impedance	1	0.14%	U.S. Acute Lead Observations	2	0.27%
■ Conductor fracture	2	0.27%	■ Lead dislodgement	2	0.27%
■ Failure to capture	2	0.27%			
■ Insulation breach	4	0.54%			
■ Lead dislodgement	6	0.82%			
■ Oversensing	7	0.95%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.
Total Survival [%]	100.0	99.1	98.1	96.4	95.1
[95% Confidence Interval]		±0.8	±1.1	±1.6	±2.1

## 9.2 Performance of ICD Leads

### Protego S Study Data

#### Product Details

Product Versions	60, 65, 75
Lead Type	single-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Jul 2014
CE Market Release	Feb 2014
Worldwide Distributed Devices	33 700
Registered U.S. Implants	876

	Quantity	Rate
U.S. Qualifying Complications	2	0.23%
■ Failure to capture	1	0.11%
■ Lead dislodgement	1	0.11%
U.S. Confirmed Malfunctions	1	0.11%
■ Conductor fracture	1	0.11%
U.S. Acute Lead Observations	3	0.34%
■ Cardiac perforation	3	0.34%



Cumulative Survival Probability after	Impl.	1 yr.
Total Survival [%]	100.0	99.8
[95% Confidence Interval]		±0.5


## 9.2 Performance of ICD Leads

### Protego SD Study Data

#### Product Details

Product Versions	60/16, 65/16, 65/18, 75/18
Lead Type	dual-coil, active fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Jul 2014
CE Market Release	May 2013
Worldwide Distributed Devices	14 700
Registered U.S. Implants	456

	Quantity	Rate
U.S. Qualifying Complications	0	0.00%
U.S. Confirmed Malfunctions	0	0.00%
U.S. Acute Lead Observations	1	0.22%
■ Lead dislodgement	1	0.22%



Cumulative Survival Probability after	Impl.	1 yr.
Total Survival [%]	100.0	100.0
[95% Confidence Interval]		




## 9.3 Performance of CRT Leads

### Corox Study Data

#### Product Details

Product Versions	OTW 75-BP Steroid, 85-BP Steroid
Lead Type	helix fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	May 2008
CE Market Release	Dec 2006
Worldwide Distributed Devices	27 400
Registered U.S. Implants	695

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	33	4.59%	U.S. Confirmed Malfunctions	6	0.72%
■ Abnormal pacing impedance	4	0.57%	■ Conductor fracture	6	0.72%
■ Conductor fracture	5	0.86%	U.S. Acute Lead Observations	4	0.72%
■ Extracardiac stimulation	3	0.14%	■ Extracardiac stimulation	1	0.14%
■ Failure to capture	5	0.57%	■ Lead dislodgement	3	0.57%
■ Lead dislodgement	16	2.15%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.
Total Survival [%]	100.0	98.3	97.1	95.4	94.7	93.4
[95% Confidence Interval]		±1.0	±1.4	±1.8	±2.0	±2.3


## 9.3 Performance of Corox Pacing Leads

### Corox Study Data

#### Product Details

Product Versions	OTW-L 75-BP, Corox OTW-L 85-BP
Lead Type	dual-curve fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	Jan 2011
CE Market Release	Dec 2009
Worldwide Distributed Devices	29 300
Registered U.S. Implants	698

	Quantity	Rate
U.S. Qualifying Complications	19	2.72%
■ Extracardiac stimulation	4	0.57%
■ Failure to capture	6	0.86%
■ Lead dislodgement	9	1.29%
U.S. Confirmed Malfunctions	0	0.00%
U.S. Acute Lead Observations	4	0.57%
■ Extracardiac stimulation	3	0.43%
■ Lead dislodgement	1	0.14%



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.
Total Survival [%]	100.0	98.5	97.2	97.0	96.6	96.6
[95% Confidence Interval]		±1.0	±1.4	±1.4	±1.6	±1.6


## 9.3 Performance of Corox Pacing Leads

### Corox Study Data

#### Product Details

Product Versions	OTW-S 75-BP, 85-BP
Lead Type	thread fixation
Polarity	bipolar
Steroid	yes
U.S. Market Release	May 2008
CE Market Release	Dec 2006
Worldwide Distributed Devices	25300
Registered U.S. Implants	1141

	Quantity	Rate		Quantity	Rate
U.S. Qualifying Complications	43	3.77%	U.S. Acute Lead Observations	6	0.53%
■ Abnormal pacing impedance	10	0.88%	■ Extracardiac stimulation	1	0.09%
■ Extracardiac stimulation	9	0.79%	■ Failure to capture	1	0.09%
■ Failure to capture	8	0.70%	■ Lead dislodgement	4	0.35%
■ Lead dislodgement	16	1.40%			
U.S. Confirmed Malfunctions	1	0.09%			
■ Insulation breach	1	0.09%			



Cumulative Survival Probability after	Impl.	1 yr.	2 yr.	3 yr.	4 yr.	5 yr.
Total Survival [%]	100.0	98.1	97.2	96.6	95.5	94.4
[95% Confidence Interval]		±0.8	±1.0	±1.2	±1.4	±1.8

## 10 Advisories

---

### Stratos LV-T

Potentially defective low voltage capacitors  
84 devices world-wide, none in the United States

### Status Update

As of July 2016

- No reports of malfunctioning pacemakers associated with this capacitor lot were received.
- No reports of deaths or serious injuries were received associated with this advisory.
- An extended test program yielded no malfunctions of the capacitors under question.

### Original communication July 2006

A limited number of our Stratos LV-T pacemakers may exhibit a device malfunction resulting in increased battery current and in loss of output, very likely simultaneously on all channels.

BIOTRONIK has identified a specific batch of low voltage capacitors from a single component supplier as the root cause. Please be assured that the capacitors from this batch are no longer being used in any BIOTRONIK device, and that no other pacemaker or ICD manufactured by BIOTRONIK is affected.

To date, no field reports related to this phenomenon were received.

The anomaly is limited to 84 devices world-wide. BIOTRONIK has taken immediate action to retrieve all potentially affected devices not yet delivered to hospitals. According to our records, 14 devices were delivered to hospitals and may have been implanted.

Based on preliminary data received from the component supplier, the projected rate of occurrence is expected to less than 1 out of 1000 devices.

Our records show that you are the implanting and/or follow-up physician for one or more patients with an affected device. We recommend the following actions:

- If Home Monitoring is activated, please check the Cardio Report and the pacing impedance history. A rapid and significant increase of the pacing impedance on one or more channels may indicate a possible loss of output. In this case we recommend to schedule a patient follow-up as soon as possible.
- If Home Monitoring is not activated or pacing impedance data from Cardio Reports are not available we recommend to schedule a patient follow-up as soon as possible.
- During a follow-up session please perform the "Battery Lead Telemetry" test. A significantly increased pacing impedance on one or more channels or a significantly increased battery current may indicate a possible loss of output.
- If no anomaly is detected please activate Home Monitoring. You may use regular follow-up intervals if Home Monitoring is used for remote monitoring between follow-ups.
- In any case we recommend to replace the device of a pacemaker-dependent patient without underlying intrinsic rhythm.

We have tried to be as specific as possible with our recommendations. As always, individual circumstances and medical judgement determine decisions about patient care, the urgency of follow-ups and possible replacement of devices.

If a Stratos LV-T is replaced for the reason explained in this notification, BIOTRONIK will provide a replacement device consistent with the terms of our warranty. For activation of the warranty, please return the explanted device to BIOTRONIK within 30 days of the explantation.

# 11 X-Ray Identifiers for Pacemakers and ICDs

---

Pacemaker/ICD Product Versions	X-Ray ID
Actros DR, Actros D, Actros SLR, Actros SR, Actros S	LC
Axios DR, Axios D, Axios SLR, Axios SR, Axios S	ER
Cylos DR, Cylos DR-T, Cylos VR	RZ
Cylos 990 DR, Cylos 990 DR-T, Cylos 990 VR	FV
Evia DR, Evia DR-T, Evia SR, Evia SR-T, Evia HF-T	SF
Estella DR, Estella DR-T, Estella SR, Estella SR-T	SF
Entovis DR, Entovis DR-T, Entovis SR, Entovis SR-T	SF
Eluna 8 DR, Eluna 8 DR-T	SF
Ilesto 7 DR-T, Ilesto 7 HF-T, Ilesto 7 VR-T DX, Ilesto 7 DR-T DF4	NT
Lexos DR, Lexos DR-T, Lexos A+, Lexos A+/T, Lexos VR, Lexos VR-T	KV
Lumax 340 DR-T, Lumax 340 HF-T, Lumax 340 VR-T	HR
Lumax 540 DR-T, Lumax 540 HF-T, Lumax 540 VR-T	SH
Lumax 740 DR-T, Lumax 740 HF-T, Lumax 740 VR-T, Lumax 740 VR-T DX	RH
Lumos DR-T, Lumos VR-T	LT
Philos DR, Philos D, Philos SLR, Philos SR, Philos S	LE
Philos DR-T	VV
Philos II DR, Philos II D, Philos II S, Philos II SLR, Philos II SR	ET
Philos II DR-T	KP
Stratos LV, Stratos LV-T	SV
Talos DR, Talos D, Talos SLR, Talos SR, Talos S	PV
Protos DR/CLS, Protos VR/CLS	EZ

## 12 Index

### Single-Chamber Pacemakers

Actros S, Actros SR	14
Axios S, Axios SR	15
Cylos VR, Cylos 990 VR	16
Eluna 8 SR, Eluna 8 SR-T	17
Entovis SR, Entovis SR-T	18
Estella SR, Estella SR-T	19
Evia SR, Evia SR-T	20
Philos II S, Philos II SR, Talos S, Talos SR	21
Philos S, Philos SR	22
Protos VR/CLS	23

### Dual-Chamber Pacemakers

Actros D, Actros DR, Actros SLR	24
Axios D, Axios DR, Axios SLR	25
Cylos DR, Cylos DR-T, Cylos 990 DR, Cylos 990 DR-T	26
Eluna 8 DR, Eluna 8 DR-T	27
Entovis DR, Entovis DR-T	28
Estella DR, Estella DR-T	29
Etrinsa 8 DR-T	30
Evia DR, Evia DR-T	31
Philos D, Philos DR, Philos DR-T, Philos SLR	32
Philos II D, Philos II DR(-T), Philos II SLR, Talos D, Talos DR, Talos SLR	33
Protos DR/CLS	34

### CRT Pacemakers

Evia HF, Evia HF-T	35
Stratos LV, Stratos LV-T	36

### Single-Chamber ICDs

Ilesto 7 VR-T	40
Lexos VR, Lexos VR-T	41
Lumax 340 VR, Lumax 340 VR-T	42
Lumax 540 VR-T	43
Lumax 740 VR-T	44
Lumos VR-T	45

### Dual-Chamber ICDs

Iforia 7 VR-T DX	46
Ilesto 7 DR-T	47
Ilesto 7 DF4 DR-T	48
Ilesto 7 VR-T DX	49
Lexos DR, Lexos DR-T, Lexos A+, Lexos A+/T	50
Lumax 340 DR, Lumax 340 DR-T	51
Lumax 540 DR-T	52
Lumax 740 DR-T	53
Lumax 740 VR-T DX	54
Lumos DR-T	55

### CRT ICDs

Ilesto 7 HF-T	56
Lumax 340 HF, Lumax 340 HF-T	57
Lumax 540 HF-T	58
Lumax 740 HF-T	59

### Pacing Leads

Arox 53-BP, 60-BP	68
Arox 45-JBP, 53-JBP	69
Dextrus Model 4135, 4136, 4137	70
Elox 45-BP, 53-BP, 60-BP	70
Elox P 45-BP, 53-BP, 60-BP	72
Polyrox 60-UP, 53-BP, 53/15-BP, 60-BP, 60/15-BP	73
Polyrox 45-JBP, 53-JBP, 53-JUP	74
Retrox 45-JBP, 53-JBP	75
Selox JT 45, JT 53	76
Selox SR 45, SR 53, SR 60	77
Selox ST 53, ST 60	78
Setrox S-45, S-53, S-60	79
Synox 60-UP, 53-BP, 60-BP	80
Synox 45-JBP, 53-JBP	81
Tilda JT45, JT53	82
Tilda R45, R53, R60	83
Tilda T53, T60	84

### ICD Leads

Kainox SL 65, 75, 100	86
Kentrox RV 65, -Steroid, 75, -Steroid	87
Kentrox SL 65, 75, Kentrox SL 65, 75, 100 Steroid	89
Kentrox SL-S 65/16, 18 Steroid	88
Lincox S 65, Lincox S 75	90
Lincox SD 60, 65, 75/16, 18	91
Lincox <sup>smart</sup> S 60, 65, 75	92
Lincox <sup>smart</sup> S DX 65/15, 65/17	93
Lincox <sup>smart</sup> SD 60/16, 65/16, 65/18, 75/18	94
Lincox <sup>smart</sup> TD 65/16, 65/18, 75/18	95
Lincox T 65, 75	96
Lincox TD 65, 75, 100/16, 18	97
Protego S 60, 65, 75	98
Protego SD 60/16, 65/16, 65/18, 75/18	99
Vigila 2CR 60/16, 65/18	100

### CRT Leads

Corox OTW-L 75-BP, 85-BP	101
Corox OTW-S 75-BP, 85-BP	102
Corox OTW 75-BP Steroid, 85-BP Steroid	103
Corox OTW 75-UP Steroid, 85-UP Steroid	104

# 13 Contacting BIOTRONIK

---

## Regarding This Report

BIOTRONIK invites your suggestions and questions related to this Product Performance Report. Please send your comments to:

### Worldwide CRM Technical Services

Phone +49 (0) 30 68905-1275  
Fax +49 (0) 30 68905-961275  
E-mail PPR@biotronik.com  
Address BIOTRONIK SE & Co. KG  
Attn: Regulatory Patient Safety  
Woermannkehre 1  
12359 Berlin, Germany

### Within the U.S.

Phone (888) 345-0374  
Fax (503) 635-9936  
E-mail PPR@biotronik.com  
Address BIOTRONIK, Inc.  
Attn: Compliance Department  
6024 Jean Road  
Lake Oswego, OR 97035

## Regarding Products

BIOTRONIK invites customers to call the following locations with suggestions, comments or specific questions related to BIOTRONIK products:

### Worldwide CRM Product Support

Phone + 49 (0) 30 68905-1133  
Fax + 49 (0) 30 68905-1960  
E-mail product.support@biotronik.com  
Address BIOTRONIK SE & Co. KG  
Attn: Product Support  
Woermannkehre 1  
12359 Berlin, Germany

### Within the U.S.

Phone (800) 284-6689  
Fax (800) 387-2681  
E-mail global.technical.services@biotronik.com  
Address BIOTRONIK, Inc.  
Attn: Technical Services  
6024 Jean Road  
Lake Oswego, OR 97035

---

# Product Performance Report

## January 2017



© BIOTRONIK SE & Co. KG  
All rights reserved. Specifications  
are subject to modification, revision  
and improvement.

**Worldwide**  
BIOTRONIK SE & Co. KG  
Woermannkehre 1  
12359 Berlin · Germany  
Tel +49 (0) 30 68905-0  
Fax +49 (0) 30 6852804  
[www.biotronik.com](http://www.biotronik.com)

**U.S.**  
BIOTRONIK, Inc.  
6024 Jean Road  
Lake Oswego, OR 97035-05369  
Tel (800) 547-0394 [24-hour]  
Fax (800) 291-0470  
[www.biotronik.com](http://www.biotronik.com)